<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523421001835</prism:url><dc:identifier>doi:10.1016/j.ejmech.2021.113334</dc:identifier><eid>1-s2.0-S0223523421001835</eid><prism:doi>10.1016/j.ejmech.2021.113334</prism:doi><pii>S0223-5234(21)00183-5</pii><dc:title>Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>216</prism:volume><prism:startingPage>113334</prism:startingpage><prism:pageRange>113334</prism:pagerange><articleNumber>113334</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2021-04-15</prism:coverdate><prism:coverDisplayDate>15 April 2021</prism:coverdisplaydate><prism:copyright>© 2021 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Dhokne, Prajwal</dc:creator><dc:creator>Sakla, Akash P.</dc:creator><dc:creator>Shankaraiah, Nagula</dc:creator><dc:description>
                  Small-molecule kinase inhibitors are being continuously explored as new anticancer therapeutics. Kinases are the phosphorylating enzymes which regulate numerous cellular functions such as proliferation, differentiation, migration, metabolism, and angiogenesis by activating several signalling pathways. Kinases have also been frequently found to be deregulated and overexpressed in cancerous tissues. Therefore, modulating the kinase activity by employing small molecules has emerged as a strategic approach for cancer treatment. On the other hand, oxindole motifs have surfaced as privileged scaffolds with significant multi-kinase inhibitory activity. The present review summarises recent advances in the development of oxindole based kinase inhibitors. The role of distinguished structural frameworks of oxindoles, such as 3-alkenyl oxindoles, spirooxindoles, 3-iminooxindoles and similar hydrazone derivatives have been described based on their kinase inhibition potential. Furthermore, the design strategies, mechanism of actions, structure activity relationships (SARs) and their mode of interaction with target protein have been critically highlighted.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Protein kinase inhibitors</dcterms:subject><dcterms:subject>Oxindole derivatives</dcterms:subject><dcterms:subject>3-Alkenyl oxindole</dcterms:subject><dcterms:subject>Cancer</dcterms:subject><dcterms:subject>Apoptosis</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523421001835" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523421001835" rel="scidir"/></link></coredata><objects><object ref="fx19" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="160" height="110" size="3863">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx19.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="533" height="220" size="56637">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="191" height="83" size="3983">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx23" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="76" height="78" size="2332">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx23.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="80" height="69" size="1973">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="299" size="67275">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="146" height="100" size="2979">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="533" height="385" size="43383">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="200" height="77" size="4422">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="450" size="91916">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr13.jpg?httpAccept=%2A%2F%2A</object><object ref="gr19" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="386" height="250" size="22071">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr19.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="388" height="225" size="20992">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx20" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="143" height="77" size="3137">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx20.jpg?httpAccept=%2A%2F%2A</object><object ref="gr14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="328" size="59114">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr14.jpg?httpAccept=%2A%2F%2A</object><object ref="fx26" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="122" height="197" size="5819">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx26.jpg?httpAccept=%2A%2F%2A</object><object ref="gr20" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="386" height="325" size="59554">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr20.jpg?httpAccept=%2A%2F%2A</object><object ref="gr25" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="809" height="712" size="182234">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr25.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="154" height="110" size="4750">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="74" height="63" size="1823">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx14.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="420" height="200" size="39638">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="689" height="638" size="106543">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr16" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="386" height="190" size="13281">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr16.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="689" height="516" size="86507">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx25" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="139" height="105" size="4318">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx25.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="138" height="125" size="4439">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx18.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="141" height="68" size="2969">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="227" height="101" size="5530">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx13.jpg?httpAccept=%2A%2F%2A</object><object ref="gr12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="386" height="298" size="48822">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr12.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="213" height="91" size="4556">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx15.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="689" height="569" size="120224">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx24" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="111" height="104" size="4206">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx24.jpg?httpAccept=%2A%2F%2A</object><object ref="gr18" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="809" height="468" size="79441">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr18.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="246" height="67" size="4572">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx17.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="435" size="72572">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr10.jpg?httpAccept=%2A%2F%2A</object><object ref="gr15" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="809" height="373" size="110065">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr15.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="386" height="189" size="19321">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr17" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="291" size="56362">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr17.jpg?httpAccept=%2A%2F%2A</object><object ref="gr22" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="533" height="342" size="65866">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr22.jpg?httpAccept=%2A%2F%2A</object><object ref="gr23" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="533" height="412" size="65061">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr23.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="218" height="80" size="4645">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx16.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="689" height="316" size="79212">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr11.jpg?httpAccept=%2A%2F%2A</object><object ref="fx21" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="181" height="94" size="4139">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx21.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="218" height="80" size="4939">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx12.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="218" height="86" size="4778">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx10.jpg?httpAccept=%2A%2F%2A</object><object ref="gr24" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="809" height="401" size="111988">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr24.jpg?httpAccept=%2A%2F%2A</object><object ref="gr21" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="311" height="331" size="37673">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr21.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="267" height="103" size="5908">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="149" height="81" size="3478">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx11.jpg?httpAccept=%2A%2F%2A</object><object ref="fx22" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="213" height="78" size="4259">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx22.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="689" height="395" size="63742">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="145" height="103" size="4094">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="fx19" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="150" size="3155">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx19.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="90" size="6711">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="96" size="2429">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx23" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="159" height="164" size="2971">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx23.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="189" height="164" size="3160">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="105" size="6212">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="fx9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="150" size="2765">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx9.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="158" size="4723">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="85" size="2650">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="gr13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="158" size="9690">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr13.sml?httpAccept=%2A%2F%2A</object><object ref="gr19" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="142" size="4796">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr19.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="127" size="5401">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx20" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="119" size="3309">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx20.sml?httpAccept=%2A%2F%2A</object><object ref="gr14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="116" size="6015">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr14.sml?httpAccept=%2A%2F%2A</object><object ref="fx26" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="101" height="163" size="2333">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx26.sml?httpAccept=%2A%2F%2A</object><object ref="gr20" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="194" height="164" size="9748">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr20.sml?httpAccept=%2A%2F%2A</object><object ref="gr25" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="186" height="164" size="15772">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr25.sml?httpAccept=%2A%2F%2A</object><object ref="fx8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="156" size="4004">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx8.sml?httpAccept=%2A%2F%2A</object><object ref="fx14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="193" height="164" size="3527">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx14.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="104" size="9110">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="177" height="164" size="6126">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr16" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="108" size="3305">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr16.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="164" size="7579">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="fx25" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="216" height="164" size="4250">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx25.sml?httpAccept=%2A%2F%2A</object><object ref="fx18" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="181" height="164" size="3290">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx18.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="105" size="2797">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="fx13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="97" size="2654">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx13.sml?httpAccept=%2A%2F%2A</object><object ref="gr12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="212" height="164" size="9094">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr12.sml?httpAccept=%2A%2F%2A</object><object ref="fx15" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="93" size="2316">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx15.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="199" height="164" size="9193">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="fx24" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="174" height="164" size="4211">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx24.sml?httpAccept=%2A%2F%2A</object><object ref="gr18" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="127" size="5534">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr18.sml?httpAccept=%2A%2F%2A</object><object ref="fx17" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="60" size="2149">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx17.sml?httpAccept=%2A%2F%2A</object><object ref="gr10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="153" size="6193">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr10.sml?httpAccept=%2A%2F%2A</object><object ref="gr15" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="101" size="8770">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr15.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="107" size="4275">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr17" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="103" size="5736">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr17.sml?httpAccept=%2A%2F%2A</object><object ref="gr22" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="141" size="9429">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr22.sml?httpAccept=%2A%2F%2A</object><object ref="gr23" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="212" height="164" size="7619">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr23.sml?httpAccept=%2A%2F%2A</object><object ref="fx16" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="80" size="2418">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx16.sml?httpAccept=%2A%2F%2A</object><object ref="gr11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="100" size="7127">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr11.sml?httpAccept=%2A%2F%2A</object><object ref="fx21" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="114" size="2832">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx21.sml?httpAccept=%2A%2F%2A</object><object ref="fx12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="80" size="2610">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx12.sml?httpAccept=%2A%2F%2A</object><object ref="fx10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="86" size="2496">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx10.sml?httpAccept=%2A%2F%2A</object><object ref="gr24" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="108" size="7616">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr24.sml?httpAccept=%2A%2F%2A</object><object ref="gr21" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="154" height="164" size="5300">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr21.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="84" size="2249">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="fx11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="119" size="2838">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx11.sml?httpAccept=%2A%2F%2A</object><object ref="fx22" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="80" size="2392">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx22.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="126" size="5906">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="155" size="3711">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="fx19" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="710" height="487" size="28330">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx19_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2362" height="974" size="431118">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="847" height="370" size="28961">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx23" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="339" height="349" size="14712">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx23_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="356" height="309" size="12210">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="1323" size="482053">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="650" height="446" size="23662">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2362" height="1707" size="309387">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="889" height="344" size="31788">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="1993" size="702868">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr19" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1712" height="1107" size="178926">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr19_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1721" height="998" size="146336">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx20" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="635" height="344" size="24018">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx20_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="1455" size="475884">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx26" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="544" height="879" size="43367">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx26_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr20" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1712" height="1443" size="467769">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr20_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr25" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3582" height="3154" size="1483201">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr25_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="682" height="486" size="34066">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="331" height="281" size="12976">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1859" height="886" size="335611">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3050" height="2826" size="782606">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr16" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1712" height="843" size="106777">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr16_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3050" height="2282" size="648363">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx25" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="618" height="468" size="32236">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx25_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="614" height="557" size="31823">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx18_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="625" height="300" size="21577">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1006" height="447" size="39074">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1712" height="1323" size="378057">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="945" height="403" size="31773">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx15_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3050" height="2517" size="905452">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx24" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="494" height="465" size="30865">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx24_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr18" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3582" height="2074" size="624756">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr18_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1091" height="298" size="35067">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx17_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="1927" size="505536">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr15" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3582" height="1651" size="843267">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr15_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1712" height="839" size="144734">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr17" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="1290" size="423141">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr17_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr22" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2362" height="1516" size="521337">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr22_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr23" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2362" height="1826" size="484269">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr23_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="967" height="355" size="34665">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx16_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3050" height="1398" size="621726">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx21" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="803" height="419" size="31289">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx21_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="966" height="353" size="37051">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="969" height="382" size="34695">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr24" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3582" height="1774" size="859534">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr24_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr21" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1378" height="1468" size="298942">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr21_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1182" height="456" size="44565">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="662" height="359" size="24330">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx22" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="945" height="346" size="31520">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx22_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3050" height="1748" size="475648">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="645" height="457" size="29289">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-fx7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1046068">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523421001835-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85102310084</scopus-id><scopus-eid>2-s2.0-85102310084</scopus-eid><pubmed-id>33721669</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85102310084" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20210303">2021-03-03</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20210303">2021-03-03</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20210312">2021-03-12</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20210312">2021-03-12</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-04-07T08:42:37</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523421001835</xocs:eid>
      <xocs:pii-formatted>S0223-5234(21)00183-5</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523421001835</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2021.113334</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523421X00050</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210508">2021-05-08T04:20:58.677096Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20210415</xocs:date-search-begin>
      <xocs:year-nav>2021</xocs:year-nav>
      <xocs:indexeddate epoch="1614742914">2021-03-03T03:41:54.807612Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body acknowledge affil articletitle auth authfirstini authfull authkeywords authlast highlightsabst nomenclature orcid primabst ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>216</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>216</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 216</xocs:vol-iss-suppl-text>
      <xocs:sort-order>35</xocs:sort-order>
      <xocs:first-fp>113334</xocs:first-fp>
      <xocs:article-number>113334</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>113334</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20210415</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>15 April 2021</xocs:cover-date-text>
      <xocs:cover-date-start>2021-04-15</xocs:cover-date-start>
      <xocs:cover-date-year>2021</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2021 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>STRUCTURALINSIGHTSOXINDOLEBASEDKINASEINHIBITORSANTICANCERAGENTSRECENTADVANCES</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>DHOKNE</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>P</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:nomenclature">
            <xocs:item-toc-section-title>List of abbreviations</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Oxindole based kinase inhibitors</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Receptor tyrosine kinase (RTK) inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Cyclin-dependent kinase (CDK) inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>p21-activated protein kinase 4 (PAK4) inibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Protein kinase B (Akt) inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Microtubule affinity regulating kinase 4 (MARK4) inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>Polo-like kinase (PLK4) inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>PIM1 kinase inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>PDK1 inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.9</xocs:item-toc-label>
               <xocs:item-toc-section-title>Aurora kinase inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.10</xocs:item-toc-label>
               <xocs:item-toc-section-title>AMPK inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Critical recap on oxindole based PKIs</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="bib1a">
            <xocs:ref-normalized-surname>FERGUSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>353</xocs:ref-first-fp>
            <xocs:ref-last-lp>376</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib1b">
            <xocs:ref-normalized-surname>RAUCH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>23</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>SHAPIRO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>NEXTGENERATIONKINASEINHIBITORS</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>BHULLAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>48</xocs:ref-first-fp>
            <xocs:ref-last-lp>67</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>COWANJACOB</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>541</xocs:ref-first-fp>
            <xocs:ref-last-lp>561</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>ROSKOSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>104609</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib6a">
            <xocs:ref-normalized-surname>NIGGULA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>3564</xocs:ref-first-fp>
            <xocs:ref-last-lp>3573</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib6b">
            <xocs:ref-normalized-surname>SENWAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>4061</xocs:ref-first-fp>
            <xocs:ref-last-lp>4069</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib6c">
            <xocs:ref-normalized-surname>SENWAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>34</xocs:ref-first-fp>
            <xocs:ref-last-lp>46</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib6d">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>673</xocs:ref-first-fp>
            <xocs:ref-last-lp>698</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib7a">
            <xocs:ref-normalized-surname>ROTH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1053</xocs:ref-first-fp>
            <xocs:ref-last-lp>1063</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib5b">
            <xocs:ref-normalized-surname>CHOW</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>884</xocs:ref-first-fp>
            <xocs:ref-last-lp>889</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>MOON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>237</xocs:ref-first-fp>
            <xocs:ref-last-lp>246</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib9a">
            <xocs:ref-normalized-surname>SAKLA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>8572</xocs:ref-first-fp>
            <xocs:ref-last-lp>8596</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib9b">
            <xocs:ref-normalized-surname>SHANKARAIAH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>253</xocs:ref-first-fp>
            <xocs:ref-last-lp>272</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib9c">
            <xocs:ref-normalized-surname>SHARMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>11</xocs:ref-first-fp>
            <xocs:ref-last-lp>24</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib9d">
            <xocs:ref-normalized-surname>SENWAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>3973</xocs:ref-first-fp>
            <xocs:ref-last-lp>3981</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib9e">
            <xocs:ref-normalized-surname>SINGH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>6104</xocs:ref-first-fp>
            <xocs:ref-last-lp>6155</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>4625</xocs:ref-first-fp>
            <xocs:ref-last-lp>4630</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib11a">
            <xocs:ref-normalized-surname>SESTITO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>47</xocs:ref-first-fp>
            <xocs:ref-last-lp>63</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib11b">
            <xocs:ref-normalized-surname>ISLAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>3814</xocs:ref-first-fp>
            <xocs:ref-last-lp>3818</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>NOBLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1800</xocs:ref-first-fp>
            <xocs:ref-last-lp>1805</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib13a">
            <xocs:ref-normalized-surname>HENDRYCHOVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib13b">
            <xocs:ref-normalized-surname>BHATIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>112640</xocs:ref-article-number>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib13c">
            <xocs:ref-normalized-surname>MARAK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>112571</xocs:ref-article-number>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib13d">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>111884</xocs:ref-article-number>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib13e">
            <xocs:ref-normalized-surname>YIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>111664</xocs:ref-article-number>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib13f">
            <xocs:ref-normalized-surname>GOLONKO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>111512</xocs:ref-article-number>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>HARTMANN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>470</xocs:ref-first-fp>
            <xocs:ref-last-lp>481</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>ARORA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>971</xocs:ref-first-fp>
            <xocs:ref-last-lp>979</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>ELDEHNA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>89</xocs:ref-first-fp>
            <xocs:ref-last-lp>97</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>ELDEHNA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>37</xocs:ref-first-fp>
            <xocs:ref-last-lp>53</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib18a">
            <xocs:ref-normalized-surname>SAFAIEQAMSARI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>13</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib18b">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>495</xocs:ref-first-fp>
            <xocs:ref-last-lp>504</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>AYTAC</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>858</xocs:ref-first-fp>
            <xocs:ref-last-lp>872</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>MOHAMADY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>18872</xocs:ref-first-fp>
            <xocs:ref-last-lp>18886</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>CHO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>8140</xocs:ref-first-fp>
            <xocs:ref-last-lp>8149</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>913</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>TANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1979</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>6953</xocs:ref-first-fp>
            <xocs:ref-last-lp>6960</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib25a">
            <xocs:ref-normalized-surname>FU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>309</xocs:ref-first-fp>
            <xocs:ref-last-lp>322</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib25b">
            <xocs:ref-normalized-surname>NAAZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>20</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib25c">
            <xocs:ref-normalized-surname>TANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1680</xocs:ref-first-fp>
            <xocs:ref-last-lp>1684</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib25d">
            <xocs:ref-normalized-surname>SHANKARAIAH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>42</xocs:ref-first-fp>
            <xocs:ref-last-lp>50</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib25e">
            <xocs:ref-normalized-surname>SENWAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>413</xocs:ref-first-fp>
            <xocs:ref-last-lp>424</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib25f">
            <xocs:ref-normalized-surname>ASHWINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>6157</xocs:ref-first-fp>
            <xocs:ref-last-lp>6165</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib25g">
            <xocs:ref-normalized-surname>KAMAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>3820</xocs:ref-first-fp>
            <xocs:ref-last-lp>3831</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib25h">
            <xocs:ref-normalized-surname>KAMAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1468</xocs:ref-first-fp>
            <xocs:ref-last-lp>1473</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib25i">
            <xocs:ref-normalized-surname>ODLO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>4829</xocs:ref-first-fp>
            <xocs:ref-last-lp>4838</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-first-fp>113083</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>QIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1778</xocs:ref-first-fp>
            <xocs:ref-last-lp>1786</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>QIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>115486</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>ELDEHNA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>309</xocs:ref-first-fp>
            <xocs:ref-last-lp>318</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib30a">
            <xocs:ref-normalized-surname>KRYSTOF</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>291</xocs:ref-first-fp>
            <xocs:ref-last-lp>302</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib30b">
            <xocs:ref-normalized-surname>MORGAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>131</xocs:ref-first-fp>
            <xocs:ref-last-lp>134</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>WEINBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>323</xocs:ref-first-fp>
            <xocs:ref-last-lp>330</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>CHIOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>12</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>IDOWU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>2712</xocs:ref-first-fp>
            <xocs:ref-last-lp>2715</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>ALWARHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>2031</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib35a">
            <xocs:ref-normalized-surname>YADAV</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>4356</xocs:ref-first-fp>
            <xocs:ref-last-lp>4363</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib35b">
            <xocs:ref-normalized-surname>GEDIYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1099</xocs:ref-first-fp>
            <xocs:ref-last-lp>1111</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>ALWARHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>1300</xocs:ref-first-fp>
            <xocs:ref-last-lp>1309</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>ELDEHNA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>270</xocs:ref-first-fp>
            <xocs:ref-last-lp>285</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>KAMAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>476</xocs:ref-first-fp>
            <xocs:ref-last-lp>485</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib39a">
            <xocs:ref-normalized-surname>WON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>11</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib39b">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1215</xocs:ref-first-fp>
            <xocs:ref-last-lp>1224</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>MURRAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>9446</xocs:ref-first-fp>
            <xocs:ref-last-lp>9451</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>e23362</xocs:ref-article-number>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>GUO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>3500</xocs:ref-first-fp>
            <xocs:ref-last-lp>3511</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>GUO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>197</xocs:ref-first-fp>
            <xocs:ref-last-lp>209</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>2</xocs:ref-first-fp>
            <xocs:ref-last-lp>6</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>NAGARSENKAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>646</xocs:ref-first-fp>
            <xocs:ref-last-lp>653</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>NAZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>485</xocs:ref-first-fp>
            <xocs:ref-last-lp>499</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>ANEJA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>840</xocs:ref-first-fp>
            <xocs:ref-last-lp>852</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>MANISWAMI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>59</xocs:ref-first-fp>
            <xocs:ref-last-lp>73</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>BARR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>429</xocs:ref-first-fp>
            <xocs:ref-last-lp>441</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>JUDGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>661</xocs:ref-first-fp>
            <xocs:ref-last-lp>673</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>LAUFER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>6069</xocs:ref-first-fp>
            <xocs:ref-last-lp>6087</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>SAMPSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>130</xocs:ref-first-fp>
            <xocs:ref-last-lp>146</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>SAMPSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>147</xocs:ref-first-fp>
            <xocs:ref-last-lp>169</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>SHAH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>2144</xocs:ref-first-fp>
            <xocs:ref-last-lp>2151</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>MERKEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>425</xocs:ref-first-fp>
            <xocs:ref-last-lp>436</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>SUN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>29456</xocs:ref-first-fp>
            <xocs:ref-last-lp>29466</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>FELDMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>19867</xocs:ref-first-fp>
            <xocs:ref-last-lp>19874</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>VIVANCO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>489</xocs:ref-first-fp>
            <xocs:ref-last-lp>501</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>SESTITO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>274</xocs:ref-first-fp>
            <xocs:ref-last-lp>288</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>BAVETSIAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>278</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>XIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>716</xocs:ref-first-fp>
            <xocs:ref-last-lp>724</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>DANIELE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>100</xocs:ref-first-fp>
            <xocs:ref-last-lp>114</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>DANDAPANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>687</xocs:ref-first-fp>
            <xocs:ref-last-lp>693</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>MATHESON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>112316</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>BORT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>DHOKNEX2021X113334</xocs:refkey3>
         <xocs:refkey4ai>DHOKNEX2021X113334XP</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2023-03-12T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2023-03-12T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2021 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2021-03-20T10:05:58.357Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp</xocs:funding-addon-type>
         <xocs:funding-source-document source-document-type="pii">S0223523421001835</xocs:funding-source-document>
         <xocs:funding-text>The authors are thankful to DoP, Ministry of Chemicals and Fertilizers, Govt. of India, New Delhi, for the award of NIPER fellowship. NIPER-H Research Communication No.: NIPER-H/2020/134.</xocs:funding-text>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(21)00183-5</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523421001835</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523421001835</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2021.113334</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2021-05-08T04:20:58.677096Z</xocs:timestamp>
         <xocs:cover-date-start>2021-04-15</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/MAIN/application/pdf/0e7e808cf82fe02efbddeaf081a73965/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>3879506</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>21</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523421001835-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/PREVIEW/image/png/1671e85e118acc6ae92198fd71dbc0b5/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>62839</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx19.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx19/DOWNSAMPLED/image/jpeg/2d95af9bcf51995c481f6c0b756f6c0e/fx19.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3863</xocs:filesize>
               <xocs:pixel-height>110</xocs:pixel-height>
               <xocs:pixel-width>160</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr6/DOWNSAMPLED/image/jpeg/7e565b8742b4db5a6748d02e2dc80839/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>56637</xocs:filesize>
               <xocs:pixel-height>220</xocs:pixel-height>
               <xocs:pixel-width>533</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx5/DOWNSAMPLED/image/jpeg/d66c106fd5ed0253adb2287aa2cecaa6/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3983</xocs:filesize>
               <xocs:pixel-height>83</xocs:pixel-height>
               <xocs:pixel-width>191</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx23.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx23/DOWNSAMPLED/image/jpeg/d04dbc18b14bc2f86711274cc7f42882/fx23.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2332</xocs:filesize>
               <xocs:pixel-height>78</xocs:pixel-height>
               <xocs:pixel-width>76</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx2/DOWNSAMPLED/image/jpeg/76c81171fc8506fe7d31f0c90f7eeb9a/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1973</xocs:filesize>
               <xocs:pixel-height>69</xocs:pixel-height>
               <xocs:pixel-width>80</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr9/DOWNSAMPLED/image/jpeg/c7f280ff74ce8d1d318c4fce682288aa/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>67275</xocs:filesize>
               <xocs:pixel-height>299</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx9/DOWNSAMPLED/image/jpeg/cd56c2dcf11e6ebed3e52aa13ac7b686/fx9.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2979</xocs:filesize>
               <xocs:pixel-height>100</xocs:pixel-height>
               <xocs:pixel-width>146</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr2/DOWNSAMPLED/image/jpeg/52e451805bb84225a9d5d4f0e67c7587/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>43383</xocs:filesize>
               <xocs:pixel-height>385</xocs:pixel-height>
               <xocs:pixel-width>533</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx3/DOWNSAMPLED/image/jpeg/2aabe63c2ec2cde0d7d854de9acdbf68/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4422</xocs:filesize>
               <xocs:pixel-height>77</xocs:pixel-height>
               <xocs:pixel-width>200</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr13/DOWNSAMPLED/image/jpeg/be1bff5e5e496030216cfa17b7d986b4/gr13.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>91916</xocs:filesize>
               <xocs:pixel-height>450</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr19.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr19/DOWNSAMPLED/image/jpeg/328bfb0e352a2b4285ecce10d89f6549/gr19.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr19</xocs:file-basename>
               <xocs:filename>gr19.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>22071</xocs:filesize>
               <xocs:pixel-height>250</xocs:pixel-height>
               <xocs:pixel-width>386</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr1/DOWNSAMPLED/image/jpeg/ec89c67eaa0f2b0f61cc91c5cc95d1ae/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>20992</xocs:filesize>
               <xocs:pixel-height>225</xocs:pixel-height>
               <xocs:pixel-width>388</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx20.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx20/DOWNSAMPLED/image/jpeg/cf5a7c0d3977be334c44bf46467d4039/fx20.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3137</xocs:filesize>
               <xocs:pixel-height>77</xocs:pixel-height>
               <xocs:pixel-width>143</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr14/DOWNSAMPLED/image/jpeg/7346142f23be7544bc99f5bc006b6cf9/gr14.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>59114</xocs:filesize>
               <xocs:pixel-height>328</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx26.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx26/DOWNSAMPLED/image/jpeg/17829223483e81baedeaf7efa3d58616/fx26.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5819</xocs:filesize>
               <xocs:pixel-height>197</xocs:pixel-height>
               <xocs:pixel-width>122</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr20.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr20/DOWNSAMPLED/image/jpeg/d9b7d2a88f8a53d3197c457c01291f7a/gr20.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr20</xocs:file-basename>
               <xocs:filename>gr20.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>59554</xocs:filesize>
               <xocs:pixel-height>325</xocs:pixel-height>
               <xocs:pixel-width>386</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr25.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr25/DOWNSAMPLED/image/jpeg/63702f902ae5d1cc77a6cb7e5c5dd3d6/gr25.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr25</xocs:file-basename>
               <xocs:filename>gr25.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>182234</xocs:filesize>
               <xocs:pixel-height>712</xocs:pixel-height>
               <xocs:pixel-width>809</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx8/DOWNSAMPLED/image/jpeg/245c08ecfba115b61172241df26707ee/fx8.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4750</xocs:filesize>
               <xocs:pixel-height>110</xocs:pixel-height>
               <xocs:pixel-width>154</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx14/DOWNSAMPLED/image/jpeg/c7c2b35f9d257553b689743fdbf486d3/fx14.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1823</xocs:filesize>
               <xocs:pixel-height>63</xocs:pixel-height>
               <xocs:pixel-width>74</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx1/DOWNSAMPLED/image/jpeg/8fef53a1f11d619a84bf81eda6f25522/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>39638</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>420</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr7/DOWNSAMPLED/image/jpeg/3f4c3b18e85e40cbf4ed4db98ded90f0/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>106543</xocs:filesize>
               <xocs:pixel-height>638</xocs:pixel-height>
               <xocs:pixel-width>689</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr16.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr16/DOWNSAMPLED/image/jpeg/eeefdb42508e506511f0c4b9afe27e46/gr16.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr16</xocs:file-basename>
               <xocs:filename>gr16.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>13281</xocs:filesize>
               <xocs:pixel-height>190</xocs:pixel-height>
               <xocs:pixel-width>386</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr3/DOWNSAMPLED/image/jpeg/04f8523c2abcfb1d579ea039e52736b3/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>86507</xocs:filesize>
               <xocs:pixel-height>516</xocs:pixel-height>
               <xocs:pixel-width>689</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx25.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx25/DOWNSAMPLED/image/jpeg/0af5ad6a5ec4609d476208ce6f18f217/fx25.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4318</xocs:filesize>
               <xocs:pixel-height>105</xocs:pixel-height>
               <xocs:pixel-width>139</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx18.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx18/DOWNSAMPLED/image/jpeg/df76a4346364972449b0868831ea24db/fx18.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4439</xocs:filesize>
               <xocs:pixel-height>125</xocs:pixel-height>
               <xocs:pixel-width>138</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx4/DOWNSAMPLED/image/jpeg/771f848ab4fcff5000949ddb731aff67/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2969</xocs:filesize>
               <xocs:pixel-height>68</xocs:pixel-height>
               <xocs:pixel-width>141</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx13/DOWNSAMPLED/image/jpeg/76ff4b6f0bec086687adbe55cdd02df5/fx13.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5530</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>227</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr12/DOWNSAMPLED/image/jpeg/40d6fadc15bb348f6068175a6b2923b5/gr12.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>48822</xocs:filesize>
               <xocs:pixel-height>298</xocs:pixel-height>
               <xocs:pixel-width>386</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx15.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx15/DOWNSAMPLED/image/jpeg/d1b2473b285bd4ae7823247af190ab34/fx15.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4556</xocs:filesize>
               <xocs:pixel-height>91</xocs:pixel-height>
               <xocs:pixel-width>213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr4/DOWNSAMPLED/image/jpeg/37654afc2fe0467babd60088a1d9cfc1/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>120224</xocs:filesize>
               <xocs:pixel-height>569</xocs:pixel-height>
               <xocs:pixel-width>689</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx24.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx24/DOWNSAMPLED/image/jpeg/ebc118b29ea2e7db2f4ddd0a8c9cbb28/fx24.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4206</xocs:filesize>
               <xocs:pixel-height>104</xocs:pixel-height>
               <xocs:pixel-width>111</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr18.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr18/DOWNSAMPLED/image/jpeg/438bb7e44c2a32a67e07dfc18591f2ba/gr18.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr18</xocs:file-basename>
               <xocs:filename>gr18.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>79441</xocs:filesize>
               <xocs:pixel-height>468</xocs:pixel-height>
               <xocs:pixel-width>809</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx17.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx17/DOWNSAMPLED/image/jpeg/beae2660c5dac6ea43f4f637b39b043b/fx17.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4572</xocs:filesize>
               <xocs:pixel-height>67</xocs:pixel-height>
               <xocs:pixel-width>246</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr10/DOWNSAMPLED/image/jpeg/9b27b60b5e52c3196e25b3057aaf0090/gr10.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>72572</xocs:filesize>
               <xocs:pixel-height>435</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr15.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr15/DOWNSAMPLED/image/jpeg/275e234d35fd3692bbc23d2be9f8a78b/gr15.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr15</xocs:file-basename>
               <xocs:filename>gr15.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>110065</xocs:filesize>
               <xocs:pixel-height>373</xocs:pixel-height>
               <xocs:pixel-width>809</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr8/DOWNSAMPLED/image/jpeg/3895cdf253e1ca704a7116ce55b9d5a0/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>19321</xocs:filesize>
               <xocs:pixel-height>189</xocs:pixel-height>
               <xocs:pixel-width>386</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr17.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr17/DOWNSAMPLED/image/jpeg/4cb8c7780421ac1a01f1de1c6c87e598/gr17.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr17</xocs:file-basename>
               <xocs:filename>gr17.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>56362</xocs:filesize>
               <xocs:pixel-height>291</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr22.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr22/DOWNSAMPLED/image/jpeg/e92c44cb370e19da2f53081759513b10/gr22.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr22</xocs:file-basename>
               <xocs:filename>gr22.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>65866</xocs:filesize>
               <xocs:pixel-height>342</xocs:pixel-height>
               <xocs:pixel-width>533</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr23.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr23/DOWNSAMPLED/image/jpeg/9a1519b26f3a625daa6446b304c14d81/gr23.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr23</xocs:file-basename>
               <xocs:filename>gr23.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>65061</xocs:filesize>
               <xocs:pixel-height>412</xocs:pixel-height>
               <xocs:pixel-width>533</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx16.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx16/DOWNSAMPLED/image/jpeg/155d5e9125e833e9ef8c93280b493831/fx16.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4645</xocs:filesize>
               <xocs:pixel-height>80</xocs:pixel-height>
               <xocs:pixel-width>218</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr11/DOWNSAMPLED/image/jpeg/52681b0b9025bf2ad7ec2cd7b0e880c5/gr11.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>79212</xocs:filesize>
               <xocs:pixel-height>316</xocs:pixel-height>
               <xocs:pixel-width>689</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx21.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx21/DOWNSAMPLED/image/jpeg/2e78f4657438104771d1c88fd0be6809/fx21.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4139</xocs:filesize>
               <xocs:pixel-height>94</xocs:pixel-height>
               <xocs:pixel-width>181</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx12/DOWNSAMPLED/image/jpeg/d4bbd949ed72490de7c7c611b5876fe4/fx12.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4939</xocs:filesize>
               <xocs:pixel-height>80</xocs:pixel-height>
               <xocs:pixel-width>218</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx10/DOWNSAMPLED/image/jpeg/a5f9a65f40b0176cee835c9f0137fa07/fx10.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4778</xocs:filesize>
               <xocs:pixel-height>86</xocs:pixel-height>
               <xocs:pixel-width>218</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr24.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr24/DOWNSAMPLED/image/jpeg/c62b3289ccd6b1f81b7733c7b9629dba/gr24.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr24</xocs:file-basename>
               <xocs:filename>gr24.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>111988</xocs:filesize>
               <xocs:pixel-height>401</xocs:pixel-height>
               <xocs:pixel-width>809</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr21.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr21/DOWNSAMPLED/image/jpeg/8ce2981bdb065181ab2f9fcea8343876/gr21.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr21</xocs:file-basename>
               <xocs:filename>gr21.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37673</xocs:filesize>
               <xocs:pixel-height>331</xocs:pixel-height>
               <xocs:pixel-width>311</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx6/DOWNSAMPLED/image/jpeg/4943e778ac86be2d32fc03a89bcd83d3/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5908</xocs:filesize>
               <xocs:pixel-height>103</xocs:pixel-height>
               <xocs:pixel-width>267</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx11/DOWNSAMPLED/image/jpeg/e707e7965b6cb08451ba30dfa2b7a2f9/fx11.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3478</xocs:filesize>
               <xocs:pixel-height>81</xocs:pixel-height>
               <xocs:pixel-width>149</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx22.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx22/DOWNSAMPLED/image/jpeg/17416cf696fbc82145e47877e62bb3aa/fx22.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4259</xocs:filesize>
               <xocs:pixel-height>78</xocs:pixel-height>
               <xocs:pixel-width>213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr5/DOWNSAMPLED/image/jpeg/35ff9b651ca0add6667a159253f716ff/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>63742</xocs:filesize>
               <xocs:pixel-height>395</xocs:pixel-height>
               <xocs:pixel-width>689</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx7/DOWNSAMPLED/image/jpeg/e5273f602bf5727bcc2a411962bb0d20/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4094</xocs:filesize>
               <xocs:pixel-height>103</xocs:pixel-height>
               <xocs:pixel-width>145</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx19.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx19/THUMBNAIL/image/gif/da33705a246e0170cdd0e942a99fae8d/fx19.sml</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3155</xocs:filesize>
               <xocs:pixel-height>150</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr6/THUMBNAIL/image/gif/a7bd95aef8c52888adc5766833cfdf39/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6711</xocs:filesize>
               <xocs:pixel-height>90</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx5/THUMBNAIL/image/gif/1604ce88425eb919549bd2b0967aa0fc/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2429</xocs:filesize>
               <xocs:pixel-height>96</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx23.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx23/THUMBNAIL/image/gif/96f2d24f264644229c7642bf8bcc9774/fx23.sml</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2971</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>159</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx2/THUMBNAIL/image/gif/3567c170ec55637b3c77dbabc39aa89c/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3160</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>189</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr9/THUMBNAIL/image/gif/01ac9c3400c26cfba92575c21f80e45e/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6212</xocs:filesize>
               <xocs:pixel-height>105</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx9/THUMBNAIL/image/gif/8489549ddac2bab8bb65216db33b389d/fx9.sml</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2765</xocs:filesize>
               <xocs:pixel-height>150</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr2/THUMBNAIL/image/gif/2a729cf419f7910c62aefcde16f940ca/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4723</xocs:filesize>
               <xocs:pixel-height>158</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx3/THUMBNAIL/image/gif/d17b56e5369fb7cb02391fc5b1a0c379/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2650</xocs:filesize>
               <xocs:pixel-height>85</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr13/THUMBNAIL/image/gif/6c4c5eeb13d8c99ab14231654577a9f9/gr13.sml</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9690</xocs:filesize>
               <xocs:pixel-height>158</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr19.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr19/THUMBNAIL/image/gif/8be328276211ea6aa9e0fa2d17897a85/gr19.sml</xocs:ucs-locator>
               <xocs:file-basename>gr19</xocs:file-basename>
               <xocs:filename>gr19.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4796</xocs:filesize>
               <xocs:pixel-height>142</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr1/THUMBNAIL/image/gif/1f759ed4dacd45dc208ce441e0101a8e/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5401</xocs:filesize>
               <xocs:pixel-height>127</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx20.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx20/THUMBNAIL/image/gif/443fc03eaf78a84f4d3a66683485f160/fx20.sml</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3309</xocs:filesize>
               <xocs:pixel-height>119</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr14/THUMBNAIL/image/gif/39152be0c926ad0455694527271d86f8/gr14.sml</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6015</xocs:filesize>
               <xocs:pixel-height>116</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx26.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx26/THUMBNAIL/image/gif/f18cdca176c8083a09c7cb685c34c21a/fx26.sml</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2333</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>101</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr20.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr20/THUMBNAIL/image/gif/7e0c6b619833187341926afa7a6a4a67/gr20.sml</xocs:ucs-locator>
               <xocs:file-basename>gr20</xocs:file-basename>
               <xocs:filename>gr20.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9748</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>194</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr25.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr25/THUMBNAIL/image/gif/3aa9819c36fe74056d0a603bf467c073/gr25.sml</xocs:ucs-locator>
               <xocs:file-basename>gr25</xocs:file-basename>
               <xocs:filename>gr25.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>15772</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>186</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx8/THUMBNAIL/image/gif/e4d8413378ce024c91eebb33ceeefc93/fx8.sml</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4004</xocs:filesize>
               <xocs:pixel-height>156</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx14/THUMBNAIL/image/gif/311d74612eab58a0563efadf04352563/fx14.sml</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3527</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>193</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx1/THUMBNAIL/image/gif/a0c91903264ae4d1b035e62defd7cb35/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9110</xocs:filesize>
               <xocs:pixel-height>104</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr7/THUMBNAIL/image/gif/89f5093faaf4b57ed7fb2a2586a8dbc2/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6126</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>177</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr16.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr16/THUMBNAIL/image/gif/f0b52fef740d7e99a9bf45148cf05a73/gr16.sml</xocs:ucs-locator>
               <xocs:file-basename>gr16</xocs:file-basename>
               <xocs:filename>gr16.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3305</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr3/THUMBNAIL/image/gif/e0dcbc701b1fb73bd2482111a736d002/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7579</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx25.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx25/THUMBNAIL/image/gif/d0792b149724875a5fc1c8de8fd26abb/fx25.sml</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4250</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx18.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx18/THUMBNAIL/image/gif/49393614b5b4f60dfd40cbefbe6a81b8/fx18.sml</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3290</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>181</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx4/THUMBNAIL/image/gif/7414fa176dbc7bf010f5b60ccef95e02/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2797</xocs:filesize>
               <xocs:pixel-height>105</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx13/THUMBNAIL/image/gif/17e6ae2de709f89c61b27fa2b3e1fee1/fx13.sml</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2654</xocs:filesize>
               <xocs:pixel-height>97</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr12/THUMBNAIL/image/gif/c6e9155ad083800a49c4d5cbb1095408/gr12.sml</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9094</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>212</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx15.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx15/THUMBNAIL/image/gif/89f75c558d2795eb427da6a4365b0b10/fx15.sml</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2316</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr4/THUMBNAIL/image/gif/d8024838e486325b8def7df5ac7166ca/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9193</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>199</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx24.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx24/THUMBNAIL/image/gif/1dbb2302f1311a247be9ec324e26d4c3/fx24.sml</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4211</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>174</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr18.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr18/THUMBNAIL/image/gif/91111b688bba3afa2d86fd14077c1890/gr18.sml</xocs:ucs-locator>
               <xocs:file-basename>gr18</xocs:file-basename>
               <xocs:filename>gr18.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5534</xocs:filesize>
               <xocs:pixel-height>127</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx17.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx17/THUMBNAIL/image/gif/fd3c5fabd6d62001df8120cbdd50b82e/fx17.sml</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2149</xocs:filesize>
               <xocs:pixel-height>60</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr10/THUMBNAIL/image/gif/f21d24211d07167a14a1316579c7653d/gr10.sml</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6193</xocs:filesize>
               <xocs:pixel-height>153</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr15.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr15/THUMBNAIL/image/gif/17564a6b5ac3b3c4d23451a971c60b44/gr15.sml</xocs:ucs-locator>
               <xocs:file-basename>gr15</xocs:file-basename>
               <xocs:filename>gr15.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8770</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr8/THUMBNAIL/image/gif/306c03db9662affcf7d2d41f8e108544/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4275</xocs:filesize>
               <xocs:pixel-height>107</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr17.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr17/THUMBNAIL/image/gif/5e73064f861f46a99888f74a474609c8/gr17.sml</xocs:ucs-locator>
               <xocs:file-basename>gr17</xocs:file-basename>
               <xocs:filename>gr17.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5736</xocs:filesize>
               <xocs:pixel-height>103</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr22.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr22/THUMBNAIL/image/gif/6ff8b9c376de2d7117b05f4e6a2587d6/gr22.sml</xocs:ucs-locator>
               <xocs:file-basename>gr22</xocs:file-basename>
               <xocs:filename>gr22.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9429</xocs:filesize>
               <xocs:pixel-height>141</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr23.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr23/THUMBNAIL/image/gif/5ab092c6fb3a487cbb35b6159bc6377d/gr23.sml</xocs:ucs-locator>
               <xocs:file-basename>gr23</xocs:file-basename>
               <xocs:filename>gr23.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7619</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>212</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx16.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx16/THUMBNAIL/image/gif/a99b3e26caa14e10ecedb0aae3ce27e4/fx16.sml</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2418</xocs:filesize>
               <xocs:pixel-height>80</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr11/THUMBNAIL/image/gif/96c6b6f5fb4b7d3683c92dfb141601dc/gr11.sml</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7127</xocs:filesize>
               <xocs:pixel-height>100</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx21.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx21/THUMBNAIL/image/gif/250af6c389454fb77cf624567af62c66/fx21.sml</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2832</xocs:filesize>
               <xocs:pixel-height>114</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx12/THUMBNAIL/image/gif/50818c201e54d6828d32badec2a70898/fx12.sml</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2610</xocs:filesize>
               <xocs:pixel-height>80</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx10/THUMBNAIL/image/gif/95e225b0d1a19d1d7acb9ca44c154ca2/fx10.sml</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2496</xocs:filesize>
               <xocs:pixel-height>86</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr24.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr24/THUMBNAIL/image/gif/0444da399900b08fe14e796db5194f1c/gr24.sml</xocs:ucs-locator>
               <xocs:file-basename>gr24</xocs:file-basename>
               <xocs:filename>gr24.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7616</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr21.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr21/THUMBNAIL/image/gif/86c252d1c332a85783266bb51308eef1/gr21.sml</xocs:ucs-locator>
               <xocs:file-basename>gr21</xocs:file-basename>
               <xocs:filename>gr21.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5300</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>154</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx6/THUMBNAIL/image/gif/495d59fb7b44861062b445d2bf5309d3/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2249</xocs:filesize>
               <xocs:pixel-height>84</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx11/THUMBNAIL/image/gif/b0ed20a703a2bc4d690baebb0c16831f/fx11.sml</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2838</xocs:filesize>
               <xocs:pixel-height>119</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx22.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx22/THUMBNAIL/image/gif/71cbaf382eba6881573d51e60cf642e3/fx22.sml</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2392</xocs:filesize>
               <xocs:pixel-height>80</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr5/THUMBNAIL/image/gif/ec2d9aa73975e86a33130b36195f8f4d/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5906</xocs:filesize>
               <xocs:pixel-height>126</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx7/THUMBNAIL/image/gif/b3c9e97ab317abf8961c7ac4768f643e/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3711</xocs:filesize>
               <xocs:pixel-height>155</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx19_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx19/HIGHRES/image/jpeg/416495f5602f6dd4b5dfcd3d797da11c/fx19_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>28330</xocs:filesize>
               <xocs:pixel-height>487</xocs:pixel-height>
               <xocs:pixel-width>710</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr6/HIGHRES/image/jpeg/d2875d711c6ff011da636aebdc6c61ed/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>431118</xocs:filesize>
               <xocs:pixel-height>974</xocs:pixel-height>
               <xocs:pixel-width>2362</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx5/HIGHRES/image/jpeg/1ee1a5bbc25ed3f8942bef3ac13131b9/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>28961</xocs:filesize>
               <xocs:pixel-height>370</xocs:pixel-height>
               <xocs:pixel-width>847</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx23_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx23/HIGHRES/image/jpeg/a85eb33dfc726f8314dbf8976df1ec58/fx23_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>14712</xocs:filesize>
               <xocs:pixel-height>349</xocs:pixel-height>
               <xocs:pixel-width>339</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx2/HIGHRES/image/jpeg/7bbfe92a6a68f234089574d3f1264a32/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>12210</xocs:filesize>
               <xocs:pixel-height>309</xocs:pixel-height>
               <xocs:pixel-width>356</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr9/HIGHRES/image/jpeg/c5c603f1206b02f00f10beed8244f1a3/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>482053</xocs:filesize>
               <xocs:pixel-height>1323</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx9/HIGHRES/image/jpeg/e06ae0a1127148b5423c549694166a36/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>23662</xocs:filesize>
               <xocs:pixel-height>446</xocs:pixel-height>
               <xocs:pixel-width>650</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr2/HIGHRES/image/jpeg/5ecee1128959c5303c980e0e125e9537/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>309387</xocs:filesize>
               <xocs:pixel-height>1707</xocs:pixel-height>
               <xocs:pixel-width>2362</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx3/HIGHRES/image/jpeg/f4a1584b7b697e4446e0e760798e7006/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31788</xocs:filesize>
               <xocs:pixel-height>344</xocs:pixel-height>
               <xocs:pixel-width>889</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr13/HIGHRES/image/jpeg/f80da2de30a71337d0524d4bf4174f47/gr13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr13</xocs:file-basename>
               <xocs:filename>gr13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>702868</xocs:filesize>
               <xocs:pixel-height>1993</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr19_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr19/HIGHRES/image/jpeg/24f164eebdd840799a7246118ae60ae8/gr19_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr19</xocs:file-basename>
               <xocs:filename>gr19_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>178926</xocs:filesize>
               <xocs:pixel-height>1107</xocs:pixel-height>
               <xocs:pixel-width>1712</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr1/HIGHRES/image/jpeg/9854e29a433c8711ca0e3df2cfead43a/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>146336</xocs:filesize>
               <xocs:pixel-height>998</xocs:pixel-height>
               <xocs:pixel-width>1721</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx20_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx20/HIGHRES/image/jpeg/0b13f24ac9207fc6a0209dc153c47e45/fx20_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>24018</xocs:filesize>
               <xocs:pixel-height>344</xocs:pixel-height>
               <xocs:pixel-width>635</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr14/HIGHRES/image/jpeg/ff837752158cec642be445f9ccebb1fe/gr14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr14</xocs:file-basename>
               <xocs:filename>gr14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>475884</xocs:filesize>
               <xocs:pixel-height>1455</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx26_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx26/HIGHRES/image/jpeg/90b49d7d3d48e19ec947a7bf63918792/fx26_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>43367</xocs:filesize>
               <xocs:pixel-height>879</xocs:pixel-height>
               <xocs:pixel-width>544</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr20_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr20/HIGHRES/image/jpeg/7a9cd6a2246ecf6a2e753394db612abb/gr20_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr20</xocs:file-basename>
               <xocs:filename>gr20_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>467769</xocs:filesize>
               <xocs:pixel-height>1443</xocs:pixel-height>
               <xocs:pixel-width>1712</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr25_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr25/HIGHRES/image/jpeg/ad5c0ce2d28e9eb451a315b67e8c5c6d/gr25_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr25</xocs:file-basename>
               <xocs:filename>gr25_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1483201</xocs:filesize>
               <xocs:pixel-height>3154</xocs:pixel-height>
               <xocs:pixel-width>3582</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx8/HIGHRES/image/jpeg/b3fc56c29cec6c5d59b997f04e95400a/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34066</xocs:filesize>
               <xocs:pixel-height>486</xocs:pixel-height>
               <xocs:pixel-width>682</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx14/HIGHRES/image/jpeg/18a7a2a2d9c6c48fdc4ab5e24dc828bc/fx14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>12976</xocs:filesize>
               <xocs:pixel-height>281</xocs:pixel-height>
               <xocs:pixel-width>331</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx1/HIGHRES/image/jpeg/543f14f4e6af569135cbb223aea9ef66/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>335611</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>1859</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr7/HIGHRES/image/jpeg/b55b904cdfc3a4e01b924c883cd5bc78/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>782606</xocs:filesize>
               <xocs:pixel-height>2826</xocs:pixel-height>
               <xocs:pixel-width>3050</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr16_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr16/HIGHRES/image/jpeg/e2b3b3f26fd3c753b7492cf4d5493875/gr16_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr16</xocs:file-basename>
               <xocs:filename>gr16_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>106777</xocs:filesize>
               <xocs:pixel-height>843</xocs:pixel-height>
               <xocs:pixel-width>1712</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr3/HIGHRES/image/jpeg/ecabafffad6ccba9a1298aeba7424430/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>648363</xocs:filesize>
               <xocs:pixel-height>2282</xocs:pixel-height>
               <xocs:pixel-width>3050</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx25_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx25/HIGHRES/image/jpeg/a42d1736ea77e20bd7fd127f3a7f4df2/fx25_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>32236</xocs:filesize>
               <xocs:pixel-height>468</xocs:pixel-height>
               <xocs:pixel-width>618</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx18_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx18/HIGHRES/image/jpeg/90b521dbec020ae355306e8bf98b40eb/fx18_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31823</xocs:filesize>
               <xocs:pixel-height>557</xocs:pixel-height>
               <xocs:pixel-width>614</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx4/HIGHRES/image/jpeg/4585e6061b4542dbe8678d15716f365b/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>21577</xocs:filesize>
               <xocs:pixel-height>300</xocs:pixel-height>
               <xocs:pixel-width>625</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx13/HIGHRES/image/jpeg/479eb3e3b82343ef1a8dd467f453ce24/fx13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>39074</xocs:filesize>
               <xocs:pixel-height>447</xocs:pixel-height>
               <xocs:pixel-width>1006</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr12/HIGHRES/image/jpeg/43b7d0e68582ddc6fd239497dbf940f5/gr12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>378057</xocs:filesize>
               <xocs:pixel-height>1323</xocs:pixel-height>
               <xocs:pixel-width>1712</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx15_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx15/HIGHRES/image/jpeg/54114bdd99d21c4558453bf08f84ef41/fx15_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31773</xocs:filesize>
               <xocs:pixel-height>403</xocs:pixel-height>
               <xocs:pixel-width>945</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr4/HIGHRES/image/jpeg/e7df3f4b0d57c92fdf965adf90dda64c/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>905452</xocs:filesize>
               <xocs:pixel-height>2517</xocs:pixel-height>
               <xocs:pixel-width>3050</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx24_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx24/HIGHRES/image/jpeg/681648b4a6a1f5899cd905fa74ccd162/fx24_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30865</xocs:filesize>
               <xocs:pixel-height>465</xocs:pixel-height>
               <xocs:pixel-width>494</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr18_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr18/HIGHRES/image/jpeg/74793ab60728528c773e05294c502565/gr18_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr18</xocs:file-basename>
               <xocs:filename>gr18_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>624756</xocs:filesize>
               <xocs:pixel-height>2074</xocs:pixel-height>
               <xocs:pixel-width>3582</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx17_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx17/HIGHRES/image/jpeg/94ac9dc29327513aee3100638713a105/fx17_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>35067</xocs:filesize>
               <xocs:pixel-height>298</xocs:pixel-height>
               <xocs:pixel-width>1091</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr10/HIGHRES/image/jpeg/c34399776b02a50e9d2d253182ff4623/gr10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>505536</xocs:filesize>
               <xocs:pixel-height>1927</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr15_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr15/HIGHRES/image/jpeg/802642cb23298156ee44cdb335186102/gr15_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr15</xocs:file-basename>
               <xocs:filename>gr15_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>843267</xocs:filesize>
               <xocs:pixel-height>1651</xocs:pixel-height>
               <xocs:pixel-width>3582</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr8/HIGHRES/image/jpeg/e4fcdb337b778e674e96143720284657/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>144734</xocs:filesize>
               <xocs:pixel-height>839</xocs:pixel-height>
               <xocs:pixel-width>1712</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr17_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr17/HIGHRES/image/jpeg/dd9dc189d0659a63d80b2e00dec9c919/gr17_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr17</xocs:file-basename>
               <xocs:filename>gr17_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>423141</xocs:filesize>
               <xocs:pixel-height>1290</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr22_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr22/HIGHRES/image/jpeg/d9fcd25664377ab0204cd89c3350c52b/gr22_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr22</xocs:file-basename>
               <xocs:filename>gr22_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>521337</xocs:filesize>
               <xocs:pixel-height>1516</xocs:pixel-height>
               <xocs:pixel-width>2362</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr23_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr23/HIGHRES/image/jpeg/baf5eebb730ecff466d49892e6650629/gr23_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr23</xocs:file-basename>
               <xocs:filename>gr23_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>484269</xocs:filesize>
               <xocs:pixel-height>1826</xocs:pixel-height>
               <xocs:pixel-width>2362</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx16_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx16/HIGHRES/image/jpeg/4de16d646a02489546dddd0196c2fa43/fx16_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34665</xocs:filesize>
               <xocs:pixel-height>355</xocs:pixel-height>
               <xocs:pixel-width>967</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr11/HIGHRES/image/jpeg/a66ddafe06117dfa0a196f5ef48d705b/gr11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>621726</xocs:filesize>
               <xocs:pixel-height>1398</xocs:pixel-height>
               <xocs:pixel-width>3050</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx21_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx21/HIGHRES/image/jpeg/bfd75ea34c55c7e06507e299ff309f6e/fx21_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31289</xocs:filesize>
               <xocs:pixel-height>419</xocs:pixel-height>
               <xocs:pixel-width>803</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx12/HIGHRES/image/jpeg/1bf275eccdf668b016e483bced830146/fx12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37051</xocs:filesize>
               <xocs:pixel-height>353</xocs:pixel-height>
               <xocs:pixel-width>966</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx10/HIGHRES/image/jpeg/68ca181a0c254d19324e4c416c289515/fx10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34695</xocs:filesize>
               <xocs:pixel-height>382</xocs:pixel-height>
               <xocs:pixel-width>969</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr24_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr24/HIGHRES/image/jpeg/35b7ed78fa6ec1da9905e4d7fec0a544/gr24_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr24</xocs:file-basename>
               <xocs:filename>gr24_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>859534</xocs:filesize>
               <xocs:pixel-height>1774</xocs:pixel-height>
               <xocs:pixel-width>3582</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr21_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr21/HIGHRES/image/jpeg/8149d3e4540ada82f3f3ed98ab23f694/gr21_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr21</xocs:file-basename>
               <xocs:filename>gr21_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>298942</xocs:filesize>
               <xocs:pixel-height>1468</xocs:pixel-height>
               <xocs:pixel-width>1378</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx6/HIGHRES/image/jpeg/53ab6010391be1af6da7f8a5d4123081/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>44565</xocs:filesize>
               <xocs:pixel-height>456</xocs:pixel-height>
               <xocs:pixel-width>1182</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx11/HIGHRES/image/jpeg/f16938deb4d1d86bbcd4abf9db8b6bb5/fx11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>24330</xocs:filesize>
               <xocs:pixel-height>359</xocs:pixel-height>
               <xocs:pixel-width>662</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx22_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx22/HIGHRES/image/jpeg/11497b99b2f29c1159800bdeb42c81a2/fx22_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>31520</xocs:filesize>
               <xocs:pixel-height>346</xocs:pixel-height>
               <xocs:pixel-width>945</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/gr5/HIGHRES/image/jpeg/8e07226a9f63e7d6d7ae874554a48e88/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>475648</xocs:filesize>
               <xocs:pixel-height>1748</xocs:pixel-height>
               <xocs:pixel-width>3050</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-fx7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523421001835/fx7/HIGHRES/image/jpeg/e26bc86c4ec5a192e87cf6ee9e13eaed/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>29289</xocs:filesize>
               <xocs:pixel-height>457</xocs:pixel-height>
               <xocs:pixel-width>645</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523421001835-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>1046068</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:104RCVN3X5F/MAIN/application/pdf/792df270869faaeae357547787a1036f/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>113334</aid>
            <ce:article-number>113334</ce:article-number>
            <ce:pii>S0223-5234(21)00183-5</ce:pii>
            <ce:doi>10.1016/j.ejmech.2021.113334</ce:doi>
            <ce:copyright type="full-transfer" year="2021">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Function of protein kinase.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0015" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523421001835/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">(a) Structures of sunitinib and nintedanib; (b) Structural characteristics of anti-kinase oxindoles.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523421001835/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Design strategy, SAR and interactions of <ce:bold>8b</ce:bold> with VEGFR2.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523421001835/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Structures, SAR and interactions of compound <ce:bold>9</ce:bold> as RTK inhibitors and interaction study of compound <ce:bold>10</ce:bold> with VEGFR-2.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523421001835/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">Structures of 3-alkenyl oxindole containing RTKs.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523421001835/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">SAR and interactions of <ce:bold>14</ce:bold> with VEGFR-2.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S0223523421001835/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Design strategy, SAR and interactions of <ce:bold>16</ce:bold> with RTK.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S0223523421001835/gr7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Structures of EGFR inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:href="pii:S0223523421001835/gr8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Fig. 9</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">Structure of compound <ce:bold>18</ce:bold> and SAR of structurally-modified meisoindigo derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Fig. 9</ce:alt-text>
               <ce:link locator="gr9" xlink:href="pii:S0223523421001835/gr9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig10">
               <ce:label>Fig. 10</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">Structure of compound <ce:bold>19</ce:bold> and <ce:bold>20</ce:bold>; interaction of compound <ce:bold>19a</ce:bold> with CDK4.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Fig. 10</ce:alt-text>
               <ce:link locator="gr10" xlink:href="pii:S0223523421001835/gr10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig11">
               <ce:label>Fig. 11</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Structure of compound <ce:bold>21</ce:bold>, its SAR and molecular docking interactions with CDK2 and GSK-3β.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0065" role="short">Fig. 11</ce:alt-text>
               <ce:link locator="gr11" xlink:href="pii:S0223523421001835/gr11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig12">
               <ce:label>Fig. 12</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="fspara0065" view="all">Structures of <ce:bold>22</ce:bold> and its interactions in the active pocket of CDK4.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0070" role="short">Fig. 12</ce:alt-text>
               <ce:link locator="gr12" xlink:href="pii:S0223523421001835/gr12" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig13">
               <ce:label>Fig. 13</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="fspara0070" view="all">Design strategy, SAR study of 3-alkenyl oxindole based PAK4 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0075" role="short">Fig. 13</ce:alt-text>
               <ce:link locator="gr13" xlink:href="pii:S0223523421001835/gr13" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig14">
               <ce:label>Fig. 14</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="fspara0075" view="all">Structures of PAK4 inhibitors and interactions of compound <ce:bold>24c</ce:bold> with PAK4.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0080" role="short">Fig. 14</ce:alt-text>
               <ce:link locator="gr14" xlink:href="pii:S0223523421001835/gr14" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig15">
               <ce:label>Fig. 15</ce:label>
               <ce:caption id="cap0080">
                  <ce:simple-para id="fspara0080" view="all">Structures and SAR of compound <ce:bold>25</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0085" role="short">Fig. 15</ce:alt-text>
               <ce:link locator="gr15" xlink:href="pii:S0223523421001835/gr15" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig16">
               <ce:label>Fig. 16</ce:label>
               <ce:caption id="cap0085">
                  <ce:simple-para id="fspara0085" view="all">Representative structure of Akt inhibitor <ce:bold>26</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0090" role="short">Fig. 16</ce:alt-text>
               <ce:link locator="gr16" xlink:href="pii:S0223523421001835/gr16" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig17">
               <ce:label>Fig. 17</ce:label>
               <ce:caption id="cap0090">
                  <ce:simple-para id="fspara0090" view="all">SAR and interactions of isatin-triazole-hydrazone hybrid <ce:bold>27</ce:bold> with MARK4.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0095" role="short">Fig. 17</ce:alt-text>
               <ce:link locator="gr17" xlink:href="pii:S0223523421001835/gr17" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig18">
               <ce:label>Fig. 18</ce:label>
               <ce:caption id="cap0095">
                  <ce:simple-para id="fspara0095" view="all">Development of lead CFI-400945 scaffolds.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0100" role="short">Fig. 18</ce:alt-text>
               <ce:link locator="gr18" xlink:href="pii:S0223523421001835/gr18" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig19">
               <ce:label>Fig. 19</ce:label>
               <ce:caption id="cap0100">
                  <ce:simple-para id="fspara0100" view="all">The effect of stereochemistry on PLK4 inhibition activity.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0105" role="short">Fig. 19</ce:alt-text>
               <ce:link locator="gr19" xlink:href="pii:S0223523421001835/gr19" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig20">
               <ce:label>Fig. 20</ce:label>
               <ce:caption id="cap0105">
                  <ce:simple-para id="fspara0105" view="all">SAR and interactions of spiro-cyclopropyl oxindole based PLK inhibitors with PLK4.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0110" role="short">Fig. 20</ce:alt-text>
               <ce:link locator="gr20" xlink:href="pii:S0223523421001835/gr20" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig21">
               <ce:label>Fig. 21</ce:label>
               <ce:caption id="cap0110">
                  <ce:simple-para id="fspara0110" view="all">Structure and interactions of <ce:bold>34</ce:bold> with PIM1 kinase.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0115" role="short">Fig. 21</ce:alt-text>
               <ce:link locator="gr21" xlink:href="pii:S0223523421001835/gr21" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig22">
               <ce:label>Fig. 22</ce:label>
               <ce:caption id="cap0115">
                  <ce:simple-para id="fspara0115" view="all">Structure and SAR of 3-alkenyl oxindole based PDK1 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0120" role="short">Fig. 22</ce:alt-text>
               <ce:link locator="gr22" xlink:href="pii:S0223523421001835/gr22" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig23">
               <ce:label>Fig. 23</ce:label>
               <ce:caption id="cap0120">
                  <ce:simple-para id="fspara0120" view="all">Structures of Aurora kinase inhibitors <ce:bold>36</ce:bold> and <ce:bold>37</ce:bold>; Interaction diagram of SA16 (<ce:bold>37</ce:bold>) docked in the Aurora A binding site.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0125" role="short">Fig. 23</ce:alt-text>
               <ce:link locator="gr23" xlink:href="pii:S0223523421001835/gr23" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig24">
               <ce:label>Fig. 24</ce:label>
               <ce:caption id="cap0125">
                  <ce:simple-para id="fspara0125" view="all">Structure of <ce:bold>38</ce:bold> and its SAR and molecular docking interactions with AMPK.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0130" role="short">Fig. 24</ce:alt-text>
               <ce:link locator="gr24" xlink:href="pii:S0223523421001835/gr24" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig25">
               <ce:label>Fig. 25</ce:label>
               <ce:caption id="cap0130">
                  <ce:simple-para id="fspara0130" view="all">Structural insights of oxindole based protein kinase inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0135" role="short">Fig. 25</ce:alt-text>
               <ce:link locator="gr25" xlink:href="pii:S0223523421001835/gr25" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0135">
                  <ce:simple-para id="tspara0010" view="all">Various structures of 3-alkenyl oxindoles as PKIs.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0145" role="short">Table 1</ce:alt-text>
               <ce:link locator="fx2" xlink:href="pii:S0223523421001835/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="5">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">S. No.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Chemical structures</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Target kinase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IC<inf loc="post">50</inf> value</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">References</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">
                           <inline-figure baseline="0.0">
                              <link locator="fx3" xlink:href="pii:S0223523421001835/fx3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0150" role="short">Image 3</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">VEGFR-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24.7 nM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">
                           <italic>Ref. 22</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDGFRβ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.1 nM</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523421001835/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0155" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">RTK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.24 ± 0.03 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>Ref. 23</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx5" xlink:href="pii:S0223523421001835/fx5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0160" role="short">Image 5</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">VEGFR-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26.38 ± 1.09 nM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>Ref. 26</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">
                           <inline-figure baseline="0.0">
                              <link locator="fx6" xlink:href="pii:S0223523421001835/fx6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0165" role="short">Image 6</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">VEGFR-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.5 nM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">
                           <italic>Ref. 28</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDGFRβ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.9 nM</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx7" xlink:href="pii:S0223523421001835/fx7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0170" role="short">Image 7</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PAK4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16 nM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>Ref. 42</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx8" xlink:href="pii:S0223523421001835/fx8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0175" role="short">Image 8</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PAK4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">25 nM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>Ref. 43</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx9" xlink:href="pii:S0223523421001835/fx9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0180" role="short">Image 9</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PIM1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>Ref. 56</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx10" xlink:href="pii:S0223523421001835/fx10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0185" role="short">Image 10</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.98 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>Ref. 58</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx11" xlink:href="pii:S0223523421001835/fx11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0190" role="short">Image 11</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Aurora A</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>Ref. 60</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">
                           <inline-figure baseline="0.0">
                              <link locator="fx12" xlink:href="pii:S0223523421001835/fx12" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0195" role="short">Image 12</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Aurora A</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">35 nM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">
                           <italic>Ref. 61</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">416 nM</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">
                           <inline-figure baseline="0.0">
                              <link locator="fx13" xlink:href="pii:S0223523421001835/fx13" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0200" role="short">Image 13</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AMPKα1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">93 ± 8 nM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">
                           <italic>Ref. 62</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AMPKα2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.2 ± 7.4 nM</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl2" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0140">
                  <ce:simple-para id="tspara0015" view="all">Various examples of 3-iminooxindole and hydrazone derivatives of oxindole as PKIs.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0210" role="short">Table 2</ce:alt-text>
               <ce:link locator="fx14" xlink:href="pii:S0223523421001835/fx14" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="5">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">S. No.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Chemical structures</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Target kinase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IC<inf loc="post">50</inf> value</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">References</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx15" xlink:href="pii:S0223523421001835/fx15" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0215" role="short">Image 15</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">VEGFR-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.31 ± 0.04 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>Ref. 16</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="2" role="rowgroup">2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="2" role="rowgroup">
                           <inline-figure baseline="0.0">
                              <link locator="fx16" xlink:href="pii:S0223523421001835/fx16" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0220" role="short">Image 16</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">VEGFR-2 FGFR-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.18 ± 0.01 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="2" role="rowgroup">
                           <italic>Ref. 17</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.23 ± 0.01 μM</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDGFR-β</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.10 ± 0.01 μM</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="2" role="rowgroup">3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="2" role="rowgroup">
                           <inline-figure baseline="0.0">
                              <link locator="fx17" xlink:href="pii:S0223523421001835/fx17" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0225" role="short">Image 17</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">VEGFR-2 FGFR-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.28 ± 0.03 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="2" role="rowgroup">
                           <italic>Ref. 17</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.46 ± 0.04 μM</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDGFR- β</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.09 ± 0.01 μM</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="2" role="rowgroup">4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="2" role="rowgroup">
                           <inline-figure baseline="0.0">
                              <link locator="fx18" xlink:href="pii:S0223523421001835/fx18" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0230" role="short">Image 18</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">VEGFR-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">435 nM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="2" role="rowgroup">
                           <italic>Ref. 20</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDGFR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">371 nM</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">C-Met</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">654 nM</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx19" xlink:href="pii:S0223523421001835/fx19" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0235" role="short">Image 19</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CDK-4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.26 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>Ref. 35</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx20" xlink:href="pii:S0223523421001835/fx20" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0240" role="short">Image 20</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CDK-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.85 ± 0.03 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>Ref. 36</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">
                           <inline-figure baseline="0.0">
                              <link locator="fx21" xlink:href="pii:S0223523421001835/fx21" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0245" role="short">Image 21</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CDK-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">38 nM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" morerows="1" role="rowgroup">
                           <italic>Ref. 37</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">GSK-3β</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">32 nM</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx22" xlink:href="pii:S0223523421001835/fx22" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0250" role="short">Image 22</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MARK-4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.54 ± 0.22 μM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>Ref. 47</italic>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl3" rowsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0145">
                  <ce:simple-para id="tspara0020" view="all">Various examples of spirooxindoles as PKIs.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0260" role="short">Table 3</ce:alt-text>
               <ce:link locator="fx23" xlink:href="pii:S0223523421001835/fx23" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="5">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">S. No.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Chemical structures</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Target kinase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IC<inf loc="post">50</inf> value</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">References</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx24" xlink:href="pii:S0223523421001835/fx24" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0265" role="short">Image 24</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">120 nM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>Ref. 29</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx25" xlink:href="pii:S0223523421001835/fx25" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0270" role="short">Image 25</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CDK4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>Ref. 34</italic>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx26" xlink:href="pii:S0223523421001835/fx26" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0275" role="short">Image 26</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PLK4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.8 ± 1.4 nM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>Ref. 53</italic>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:article-footnote>
               <ce:label>☆</ce:label>
               <ce:note-para id="ntpara0010" view="all">This article is dedicated to Dr. Ahmed Kamal for his outstanding contribution in the field of bioorganic and medicinal chemistry.</ce:note-para>
            </ce:article-footnote>
            <ce:title id="title0010">Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523421001835-cbe288e259b9f5fb987f56d7f47a7f2d">
                  <ce:given-name>Prajwal</ce:given-name>
                  <ce:surname>Dhokne</ce:surname>
               </ce:author>
               <ce:author id="au2" author-id="S0223523421001835-8900175442fb78f2673db4a84bb4d5a6">
                  <ce:given-name>Akash P.</ce:given-name>
                  <ce:surname>Sakla</ce:surname>
               </ce:author>
               <ce:author id="au3" orcid="0000-0002-8733-9431" author-id="S0223523421001835-eff2e79bb828d743c3934d4a221f2c5f">
                  <ce:given-name>Nagula</ce:given-name>
                  <ce:surname>Shankaraiah</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523421001835-989e21646212111947ac0aa6849dc94d">
                  <ce:textfn>Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, 500037, India</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Medicinal Chemistry</sa:organization>
                     <sa:organization>National Institute of Pharmaceutical Education and Research (NIPER)</sa:organization>
                     <sa:city>Hyderabad</sa:city>
                     <sa:postal-code>500037</sa:postal-code>
                     <sa:country>India</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, 500037, India</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="30" month="12" year="2020"/></ce:date-received>
            <ce:date-revised day="9" month="2" year="2021"/></ce:date-revised>
            <ce:date-accepted day="19" month="2" year="2021"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Small-molecule kinase inhibitors are being continuously explored as new anticancer therapeutics. Kinases are the phosphorylating enzymes which regulate numerous cellular functions such as proliferation, differentiation, migration, metabolism, and angiogenesis by activating several signalling pathways. Kinases have also been frequently found to be deregulated and overexpressed in cancerous tissues. Therefore, modulating the kinase activity by employing small molecules has emerged as a strategic approach for cancer treatment. On the other hand, oxindole motifs have surfaced as privileged scaffolds with significant multi-kinase inhibitory activity. The present review summarises recent advances in the development of oxindole based kinase inhibitors. The role of distinguished structural frameworks of oxindoles, such as 3-alkenyl oxindoles, spirooxindoles, 3-iminooxindoles and similar hydrazone derivatives have been described based on their kinase inhibition potential. Furthermore, the design strategies, mechanism of actions, structure activity relationships (SARs) and their mode of interaction with target protein have been critically highlighted.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523421001835/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Protein kinase inhibitors</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Oxindole derivatives</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>3-Alkenyl oxindole</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Cancer</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Apoptosis</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:nomenclature id="nomen0010" view="all">
               <ce:section-title id="sectitle0030">List of abbreviations</ce:section-title>
               <ce:def-list id="dlist0010">
                  <ce:def-term id="d0010">ACC</ce:def-term>
                  <ce:def-description id="defdis0010">
                     <ce:para id="p0025" view="all">: Acetyl CoA carboxylase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0015">ADMET</ce:def-term>
                  <ce:def-description id="defdis0015">
                     <ce:para id="p0030" view="all">: Absorption, Distribution, Metabolism, and Excretion</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0020">Akt</ce:def-term>
                  <ce:def-description id="defdis0020">
                     <ce:para id="p0035" view="all">: Protein kinase B</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0025">AMPKs</ce:def-term>
                  <ce:def-description id="defdis0025">
                     <ce:para id="p0040" view="all">: AMP-activated protein kinases</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0030">ATP</ce:def-term>
                  <ce:def-description id="defdis0030">
                     <ce:para id="p0045" view="all">: Adenosine triphosphate</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0035">BAD</ce:def-term>
                  <ce:def-description id="defdis0035">
                     <ce:para id="p0050" view="all">: BCL-2 associated agonist of cell death</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0040">Bcl-2</ce:def-term>
                  <ce:def-description id="defdis0040">
                     <ce:para id="p0055" view="all">: B-cell lymphoma-2</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0045">CDKs</ce:def-term>
                  <ce:def-description id="defdis0045">
                     <ce:para id="p0060" view="all">: Cyclin-dependent kinases</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0050">CHK</ce:def-term>
                  <ce:def-description id="defdis0050">
                     <ce:para id="p0065" view="all">: Checkpoint kinase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0055">c-Met</ce:def-term>
                  <ce:def-description id="defdis0055">
                     <ce:para id="p0070" view="all">: Mesenchymal-epithelial transition factor</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0060">CNS</ce:def-term>
                  <ce:def-description id="defdis0060">
                     <ce:para id="p0075" view="all">: Central nervous system</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0065">CSCs</ce:def-term>
                  <ce:def-description id="defdis0065">
                     <ce:para id="p0080" view="all">: Cancer stem cells</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0070">CSF1R</ce:def-term>
                  <ce:def-description id="defdis0070">
                     <ce:para id="p0085" view="all">: Colony stimulating factor 1 receptor</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0075">DNA</ce:def-term>
                  <ce:def-description id="defdis0075">
                     <ce:para id="p0090" view="all">: Deoxyribonucleic acid</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0080">EGFR</ce:def-term>
                  <ce:def-description id="defdis0080">
                     <ce:para id="p0095" view="all">: Epidermal growth factor receptor</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0085">ERK</ce:def-term>
                  <ce:def-description id="defdis0085">
                     <ce:para id="p0100" view="all">: Extracellular signal-regulated kinase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0090">FAK</ce:def-term>
                  <ce:def-description id="defdis0090">
                     <ce:para id="p0105" view="all">: Focal adhesion kinase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0095">FDA</ce:def-term>
                  <ce:def-description id="defdis0095">
                     <ce:para id="p0110" view="all">: Food and Drug Administration</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0100">FGFR</ce:def-term>
                  <ce:def-description id="defdis0100">
                     <ce:para id="p0115" view="all">: Fibroblast growth factor receptor</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0105">GBM</ce:def-term>
                  <ce:def-description id="defdis0105">
                     <ce:para id="p0120" view="all">: Glioblastoma multiforme</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0110">GSK</ce:def-term>
                  <ce:def-description id="defdis0110">
                     <ce:para id="p0125" view="all">: Glycogen synthase kinase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0115">HUVECs</ce:def-term>
                  <ce:def-description id="defdis0115">
                     <ce:para id="p0130" view="all">: Human umbilical vein endothelial cells</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0120">ISV</ce:def-term>
                  <ce:def-description id="defdis0120">
                     <ce:para id="p0135" view="all">: Intersegmental vessel</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0125">JAK/STAT</ce:def-term>
                  <ce:def-description id="defdis0125">
                     <ce:para id="p0140" view="all">: The Janus kinase/signal transducer and activator of transcription</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0130">LE</ce:def-term>
                  <ce:def-description id="defdis0130">
                     <ce:para id="p0145" view="all">: Ligand efficiency</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0135">LELP</ce:def-term>
                  <ce:def-description id="defdis0135">
                     <ce:para id="p0150" view="all">: Ligand-efficiency-dependent lipophilicity</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0140">LKB</ce:def-term>
                  <ce:def-description id="defdis0140">
                     <ce:para id="p0155" view="all">: Liver kinase beta</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0145">LLE</ce:def-term>
                  <ce:def-description id="defdis0145">
                     <ce:para id="p0160" view="all">: Ligand lipophilicity efficiency</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0150">MAP</ce:def-term>
                  <ce:def-description id="defdis0150">
                     <ce:para id="p0165" view="all">: Microtubule-associated protein</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0155">MARKs</ce:def-term>
                  <ce:def-description id="defdis0155">
                     <ce:para id="p0170" view="all">: Microtubule affinity regulating kinases</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0160">MTT</ce:def-term>
                  <ce:def-description id="defdis0160">
                     <ce:para id="p0175" view="all">: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0165">MYC</ce:def-term>
                  <ce:def-description id="defdis0165">
                     <ce:para id="p0180" view="all">: Myelocytomatosis</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0170">NRTKs</ce:def-term>
                  <ce:def-description id="defdis0170">
                     <ce:para id="p0185" view="all">: Non-receptor tyrosine kinases</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0175">
                     <ce:italic>p</ce:italic>-ACC</ce:def-term>
                  <ce:def-description id="defdis0175">
                     <ce:para id="p0190" view="all">: Phospho-acetyl-CoA carboxylase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0180">PAKs</ce:def-term>
                  <ce:def-description id="defdis0180">
                     <ce:para id="p0195" view="all">: p-21 activated kinases</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0185">PARP-1</ce:def-term>
                  <ce:def-description id="defdis0185">
                     <ce:para id="p0200" view="all">: Poly [ADP-ribose] polymerase-1</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0190">PDGFR</ce:def-term>
                  <ce:def-description id="defdis0190">
                     <ce:para id="p0205" view="all">: Platelet-derived growth factor receptor</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0195">PDK</ce:def-term>
                  <ce:def-description id="defdis0195">
                     <ce:para id="p0210" view="all">: 3-Phosphoinositide-dependent kinase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0200">PI3K</ce:def-term>
                  <ce:def-description id="defdis0200">
                     <ce:para id="p0215" view="all">: Phosphoinositide 3-kinase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0205">PIM</ce:def-term>
                  <ce:def-description id="defdis0205">
                     <ce:para id="p0220" view="all">: Pro-viral integration site for Moloney murine leukaemia virus</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0210">PKC</ce:def-term>
                  <ce:def-description id="defdis0210">
                     <ce:para id="p0225" view="all">: Protein kinase C</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0215">PKIs</ce:def-term>
                  <ce:def-description id="defdis0215">
                     <ce:para id="p0230" view="all">: Protein kinase inhibitors</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0220">PKs</ce:def-term>
                  <ce:def-description id="defdis0220">
                     <ce:para id="p0235" view="all">: Protein kinases</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0225">PLKs</ce:def-term>
                  <ce:def-description id="defdis0225">
                     <ce:para id="p0240" view="all">: Polo-like kinases</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0230">pRb</ce:def-term>
                  <ce:def-description id="defdis0230">
                     <ce:para id="p0245" view="all">: Retinoblastoma protein</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0235">PRKs</ce:def-term>
                  <ce:def-description id="defdis0235">
                     <ce:para id="p0250" view="all">: PKC-related kinases</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0240">PTKs</ce:def-term>
                  <ce:def-description id="defdis0240">
                     <ce:para id="p0255" view="all">: Protein tyrosine kinases</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0245">PUMA</ce:def-term>
                  <ce:def-description id="defdis0245">
                     <ce:para id="p0260" view="all">: p53 upregulated modulator of apoptosis</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0250">RTKs</ce:def-term>
                  <ce:def-description id="defdis0250">
                     <ce:para id="p0265" view="all">: Receptor tyrosine kinases</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0255">SAR</ce:def-term>
                  <ce:def-description id="defdis0255">
                     <ce:para id="p0270" view="all">: Structure activity relationship</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0260">siRNA</ce:def-term>
                  <ce:def-description id="defdis0260">
                     <ce:para id="p0275" view="all">: Small interfering RNA</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0265">SGK</ce:def-term>
                  <ce:def-description id="defdis0265">
                     <ce:para id="p0280" view="all">: Serum and glucocorticoid-regulated kinase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0270">Src</ce:def-term>
                  <ce:def-description id="defdis0270">
                     <ce:para id="p0285" view="all">: Steroid receptor coactivator</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0275">STAT3</ce:def-term>
                  <ce:def-description id="defdis0275">
                     <ce:para id="p0290" view="all">: Signal transducer and activator of transcription 3</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0280">tPSA</ce:def-term>
                  <ce:def-description id="defdis0280">
                     <ce:para id="p0295" view="all">: Topological Polar Surface Area</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0285">US FDA</ce:def-term>
                  <ce:def-description id="defdis0285">
                     <ce:para id="p0300" view="all">: The United States Food and Drug Administration</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0290">VEGFR</ce:def-term>
                  <ce:def-description id="defdis0290">
                     <ce:para id="p0305" view="all">: Vascular endothelial growth factor receptor</ce:para>
                  </ce:def-description>
               </ce:def-list>
            </ce:nomenclature>
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0035">Introduction</ce:section-title>
                  <ce:para id="p0310" view="all">Protein Kinase (PK) enzymes regulate vital cellular functions and respond to extracellular signals. There are about ∼500 different kinases based upon human genome sequencing and are assembled into ∼20 kinase families [<ce:cross-refs id="crosrefs0010" refid="bib1 bib1a bib1b">1</ce:cross-refs>]. Cellular functions, such as cell growth, differentiation and proliferation are highly regulated through delicately balanced protein phosphorylation/dephosphorylation process by kinase/phosphatase enzymes (<ce:cross-ref id="crosref0015" refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>). As a result, even a slight genomic instability or genetic mutation in the kinase gene leads to cell proliferation disorders (cancer) or inflammation-related diseases [<ce:cross-ref id="crosref0020" refid="bib2">2</ce:cross-ref>]. Recent developments in understanding the fundamental molecular mechanisms of cancer cell signalling have disclosed prominent role of kinases in metastases of various cancers [<ce:cross-ref id="crosref0025" refid="bib3">3</ce:cross-ref>]. A typical kinase consists of conserved ATP binding site, substrate interaction site, activation site and allosteric site [<ce:cross-ref id="crosref0030" refid="bib4">4</ce:cross-ref>]. Protein Kinase Inhibitors (PKIs) compete with the ATP binding site of the kinases and reduce phosphorylation of substrate protein, thereby inhibiting cell proliferation cascades. PKIs are classified based on their ability to catalyze phosphorylation of the substrate protein containing tyrosine, serine and threonine residue. In general, most of the PKIs form: a) H-bonds with catalytic spine residue; (b) interaction with the gatekeeper residue; (c) hydrophobic contacts with catalytic spine residues [<ce:cross-ref id="crosref0035" refid="bib3">3</ce:cross-ref>]. As of January 2020, 52 small molecule PKIs have been approved by US FDA, astonishingly, 46 of them are used in the treatment of cancer [<ce:cross-refs id="crosrefs0015" refid="bib5 bib5b">5</ce:cross-refs>]. Henceforth, exploring kinase space to decode its anticancer potential is highly desirable.</ce:para>
                  <ce:para id="p0315" view="all">From the past few years, oxindole based scaffolds have gained considerable attention owing to its broad pharmacological significance [<ce:cross-refs id="crosrefs0020" refid="bib6 bib6a bib6b bib6c bib6d">6</ce:cross-refs>]. It has been widely recognised in cancer therapeutics as multi-kinase inhibitors. Sunitinib (<ce:bold>1</ce:bold>) and nintedanib (<ce:bold>2</ce:bold>) are oxindole containing clinically approved drugs for the treatment of renal cell carcinoma and adenocarcinoma, respectively [<ce:cross-ref id="crosref0040" refid="bib7">7</ce:cross-ref>]. Moreover, natural oxindole derivative like indirubin has showcased potent CDK inhibition [<ce:cross-ref id="crosref0045" refid="bib8">8</ce:cross-ref>]. A closer look on various structural features of oxindole-based kinase inhibitors reveals three distinct oxindole frameworks: 3-alkenyl oxindole (<ce:bold>4</ce:bold>), 3-iminooxindole (<ce:bold>5</ce:bold>), and 3,3′-spirocyclic oxindoles (<ce:bold>6</ce:bold>) (<ce:cross-ref id="crosref0050" refid="fig2">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>). Apart from their biological importance, these C3-functionalised oxindoles are easily accessible due to well established synthetic strategies [<ce:cross-refs id="crosrefs0025" refid="bib9 bib9a bib9b bib9c bib9d bib9e">9</ce:cross-refs>]. Most of the oxindole based PKIs constitute 3-alkenyl oxindole moiety as an integral core which are also found in clinically approved drugs [<ce:cross-ref id="crosref0055" refid="bib7">7</ce:cross-ref>]. However, many research groups have disclosed bioisosteric replacement of alkene group with small cyclopropane ring or imino group resulting in improved anti-kinase activity [<ce:cross-ref id="crosref0060" refid="bib10">10</ce:cross-ref>]. In addition to C3-functionalised oxindole, substitution at aromatic ring (C5 and C6) has also showcased significant kinase inhibition [<ce:cross-refs id="crosrefs0030" refid="bib11 bib11a bib11b">11</ce:cross-refs>].</ce:para>
                  <ce:para id="p0320" view="all">Given the cardinal role of protein kinases and its inhibitors in the cancer therapeutics and other diseases, many reviews have appeared in the literature. Shapiro et al., have detailed the structure of PKs along with current approaches and alternative strategies for developing efficacious PKIs [<ce:cross-ref id="crosref0065" refid="bib2">2</ce:cross-ref>]. Recently, Roskosky highlighted the medicinal attributes of FDA approved small molecules as kinase inhibitors [<ce:cross-ref id="crosref0070" refid="bib5">5</ce:cross-ref>]. Johnson et al., discussed structural insights of PKIs currently in the clinical use or trials [<ce:cross-ref id="crosref0075" refid="bib12">12</ce:cross-ref>]. In addition, several reviews have been published either discussing various pharmacophores as particular kinase inhibitors (RTK, CDK, EGFR and FGFR) or anti-kinase properties of specific heterocycle as anticancer agents [<ce:cross-refs id="crosrefs0035" refid="bib13 bib13a bib13b bib13c bib13d bib13e">13</ce:cross-refs>]. In this regard, it is essential to comprehensively revise various structural templates of oxindoles for the successful design of small molecules as protein kinase inhibitors. In the current review, we aim to envelop the development of oxindole scaffolds as protein kinase inhibitors. Herein, we have presented various oxindole based derivatives which are reported for their anti-kinase properties including RTK, CDK, PAK4, Akt, MARK4, PLK4, PIM1, AMPK etc.</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0040">Oxindole based kinase inhibitors</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0045">Receptor tyrosine kinase (RTK) inhibitors</ce:section-title>
                     <ce:para id="p0325" view="all">RTKs catalyze phosphorylation of tyrosine by the transmission of γ-phosphate group from ATP. These are categorised as membrane-bound receptor tyrosine kinases (RTKs) and cytoplasmic non-receptor tyrosine kinases (NRTKs) [<ce:cross-ref id="crosref0080" refid="bib14">14</ce:cross-ref>]. They control the vital cellular functions such as cell proliferation, differentiation, migration, metabolism and anti-apoptotic signalling. Abnormal uncontrolled RTKs activation due to mutations or irrational over-expression leads to the cancer development, growth and progression. Therefore, RTKs are regarded as important targets in the treatment of cancer [<ce:cross-ref id="crosref0085" refid="bib15">15</ce:cross-ref>].</ce:para>
                     <ce:para id="p0330" view="all">Eldehna et al., designed 3-iminooxindole based derivatives incorporating diphenyl urea moiety from sorafenib (<ce:bold>7</ce:bold>) and evaluated for their <ce:italic>in vitro</ce:italic> antitumour activity against hepatic carcinoma (HepG2) cell lines (<ce:cross-ref id="crosref0090" refid="fig3">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor>). Importantly, compound <ce:bold>8b</ce:bold> showed potent VEGFR2 inhibition in sub-micromolar concentration (IC<ce:inf loc="post">50</ce:inf> 0.31 μM). Among the synthesized compounds, <ce:bold>8a</ce:bold> showed most potent antiproliferative activity against HepG2 cell line with IC<ce:inf loc="post">50</ce:inf> value of 1.81 μM, better than the reference drugs doxorubicin (IC<ce:inf loc="post">50</ce:inf> 2.90 ± 0.36 μM) and sorafenib (IC<ce:inf loc="post">50</ce:inf> 3.40 ± 0.25 μM). SAR studies showed that substitution on the oxindole scaffold and the phenyl group of the diphenyl urea moiety played a crucial role in the inhibition of enzymatic activity of VEGFR2. Molecular docking study indicated that compound <ce:bold>8b</ce:bold> showed five key hydrogen-bonding interactions with VEGFR2. Besides, important hydrophobic interactions were also observed in the hinge region of target protein (<ce:cross-ref id="crosref0095" refid="fig3">Fig. 3</ce:cross-ref>) [<ce:cross-ref id="crosref0100" refid="bib16">16</ce:cross-ref>].</ce:para>
                     <ce:para id="p0335" view="all">Further, same research group elaborated anticancer activity of <ce:bold>9a</ce:bold>-<ce:bold>c</ce:bold> using similar strategy to circumvent the resistance to chemotherapy acquired due to mutations in the RTKs and to improve the pharmacokinetics and toxicity profile. The kinase assay demonstrated that all the synthesized analogues had moderate to excellent inhibitory activity against VEGFR-2 with IC<ce:inf loc="post">50</ce:inf> values ranging from 0.18 to 4.40 μM (for ureido congeners) and 0.28–4.70 μM (for amido congeners). Among them, compound <ce:bold>9a</ce:bold> showed potent VEGFR-2, FGFR-1 PDGFRβ inhibitory activity. In the docking study, the designed compounds showed comparable binding pattern with that of type-IIA PTK inhibitor (sorafenib) in the catalytic cleft of the PTKs (<ce:cross-ref id="crosref0105" refid="fig4">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>). In addition, the compounds <ce:bold>9b</ce:bold> and <ce:bold>9c</ce:bold> had good pharmacokinetic profile as it showed favourable predicted oral bioavailability [<ce:cross-ref id="crosref0110" refid="bib17">17</ce:cross-ref>].</ce:para>
                     <ce:para id="p0340" view="all">The ligands that act by only inhibition of VEGFR tend to induce expression of c-Met. Activation of c-Met triggers multiple signalling cascades including Src/FAK, STAT3, PI3K/Akt, and RAS which contribute in angiogenesis, by directly stimulating endothelial cell growth or by indirectly elevating the expression of angiogenic factors such as VEGF. Such activation of c-Met is found to be one of the major reasons for resistance and failure of VEGFR inhibitors. Therefore, dual inhibition of VEGFR-2 and c-Met by molecular hybrids has been most effective therapeutic approach for cancer treatment [<ce:cross-ref id="crosref0115" refid="bib18">18</ce:cross-ref>]. On the other hand, triazolothiadiazine derivatives have elucidated significant cytotoxicity against epithelial cancer cells [<ce:cross-ref id="crosref0120" refid="bib19">19</ce:cross-ref>]. Mohamady et al., demonstrated potential of 3-triazolothiadiazine-oxindole conjugates as VEGFR2 and c-Met kinase inhibitors [<ce:cross-ref id="crosref0125" refid="bib20">20</ce:cross-ref>]. Particularly, compound <ce:bold>10</ce:bold> with 5-methoxy substitution exhibited potent VEGFR2, PDGFR and c-Met inhibitory activity with IC<ce:inf loc="post">50</ce:inf> values of 435, 371 and 654 nM, respectively. The docking studies on compound <ce:bold>10</ce:bold> with VEGFR-2 showed that the oxindole moiety could form hydrogen-bonding with Cys919 and Glu917. Moreover, the triazine and the phenyl rings aided in binding to the catalytic pocket by forming π-hydrophobic interaction and π-cation interaction with Leu840 and Lys838, respectively (<ce:cross-ref id="crosref0130" refid="fig4">Fig. 4</ce:cross-ref>).</ce:para>
                     <ce:para id="p0345" view="all">Jun and his research group carried out extensive modifications in the structure of sunitinib and demonstrated that ring closure of the amide at C4 to methyl group at C5 of the pyrrole ring indeed gave rise to more potent compounds [<ce:cross-ref id="crosref0135" refid="bib21">21</ce:cross-ref>]. With this rationale, Lee et al., synthesized a series of 2-pyrrolidone-fused [(2-oxoindolin-3-ylidene)methyl]pyrrole derivatives as multikinase inhibitors (<ce:cross-ref id="crosref0140" refid="fig5">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>) [<ce:cross-ref id="crosref0145" refid="bib22">22</ce:cross-ref>]. Particularly, compound <ce:bold>11a</ce:bold> with 5-Br substitution exhibited significant VEGFR-2 and PDGF-β inhibition (IC<ce:inf loc="post">50</ce:inf> = 24.7 and 16.1 nM, respectively). Cytotoxicity evaluation indicated that compound <ce:bold>11a</ce:bold> and <ce:bold>11b</ce:bold> showed potent inhibition of HCT-116 cell line with IC<ce:inf loc="post">50</ce:inf> value of 1.05 ± 0.18 μM and 0.42 ± 0.16 μM. Mechanistically, these compounds induced apoptosis <ce:italic>via</ce:italic> activation of p53 upregulated modulator of apoptosis (PUMA) certainly due to inhibition of aurora kinase. Fluoro substitution at C5-position showed poor VEGFR-2 and PDGF-β inhibitory activity in comparison with other halogen substitutions (Cl, Br, I) indicating that proper substituent at C5-position of oxindole played a key role in their inhibition. Furthermore, compound <ce:bold>11a</ce:bold> could inhibit the tube formation (IC<ce:inf loc="post">50</ce:inf> = 179 ± 29 nM, two-fold more potent than sunitinib) <ce:italic>via</ce:italic> inhibiting VEGFR-2 pathway in a dose-dependent manner.</ce:para>
                     <ce:para id="p0350" view="all">On the other hand, 3-alkenyl oxindole bearing benzyl sulfoxide moiety was reported for their tyrosine kinase inhibitory activity (<ce:bold>12a</ce:bold>; IC<ce:inf loc="post">50</ce:inf> 1.34 ± 0.03 μM, <ce:bold>12b</ce:bold>; IC<ce:inf loc="post">50</ce:inf> 2.23 ± 0.14 μM). These compounds also showcased reasonable cytotoxicity on HeLa cancer cells (18–24 μM). Substitution of benzyl sulfoxide with 4-bromo or 3-methoxy group resulted in significant inhibition of tyrosine kinase enzyme [<ce:cross-ref id="crosref0150" refid="bib23">23</ce:cross-ref>]. Inspired by the triple kinase inhibitory potential of nintedanib and SU6668, Zhang and Liang et al., reported a series of compounds <ce:bold>13</ce:bold> based on the structure of ATP binding domain. <ce:bold>13a</ce:bold> and <ce:bold>13b</ce:bold> showed weak inhibitory activity against FGFR1, whereas demonstrated highest inhibitory effect on c-kit kinases with IC<ce:inf loc="post">50</ce:inf> values of 128 nM and 71 nM, respectively. Compound <ce:bold>13b</ce:bold> displayed antiproliferative potential with IC<ce:inf loc="post">50</ce:inf> values of 2.76 ± 2.83 and 2.85 ± 0.21 μM against ovarian (PM8910) and gastric (SGC7901) cancer cell lines. Furthermore, <ce:bold>13a</ce:bold>,<ce:bold>b</ce:bold> arrested cell cycle in G0/G1 phase in A549 cell lines. Docking simulation studies of <ce:bold>13a</ce:bold>,<ce:bold>b</ce:bold> with ATP binding site of c-Kit kinase enzyme revealed hydrogen bonding interaction of amino acids Cys673 and Glu671 with <ce:italic>O</ce:italic> and -<ce:italic>NH</ce:italic> atoms of compounds. In addition, carbonyl of piperazine moiety forms two-hydrogen bonds with Lys593 and Glu758 [<ce:cross-ref id="crosref0155" refid="bib24">24</ce:cross-ref>].</ce:para>
                     <ce:para id="p0355" view="all">1,2,3-Triazole scaffolds have been extensively explored due to their ability to interact with various biological targets [<ce:cross-refs id="crosrefs0040" refid="bib25 bib25a bib25b bib25c bib25d bib25e bib25f bib25g">25</ce:cross-refs>]. Meng et al., synthesized novel 3-alkenyl oxindole derivatives hybridised with 1,4-diphenyl-1<ce:italic>H</ce:italic>-1,2,3-triazole and assessed their antiangiogenic potential by performing <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> studies. Compound <ce:bold>14</ce:bold> with 4-methylphenyl substitution on triazole moiety potentially inhibited VEGFR-2 with IC<ce:inf loc="post">50</ce:inf> value of 26.38 nM (better than that of positive control sunitinib IC<ce:inf loc="post">50</ce:inf> = 83.20 nM). Moreover, compound <ce:bold>14</ce:bold> was able to inhibit the proliferation of human colon cancer (HT-29) and human gastric cancer (MKN-45) cell lines with IC<ce:inf loc="post">50</ce:inf> values of 1.61 ± 0.45 and 1.92 ± 0.37 μM respectively, being more potent than sunitinib, but was less toxic to human umbilical vein endothelial cells (HUVECs) (<ce:cross-ref id="crosref0160" refid="fig5">Fig. 5</ce:cross-ref>). The substitutions on the oxindole core did not affect the inhibitory activity, however electron-donating substituents showed enhanced inhibitory activity than electron-withdrawing groups on the triazole ring (<ce:cross-ref id="crosref0165" refid="fig6">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>). Mechanistically, compound <ce:bold>14</ce:bold> inhibited HUVEC’s migration and tube formation in a dose dependent manner. In addition, compound <ce:bold>14</ce:bold> at 40 mg/L concentration inhibited intersegmental vessel (ISV) angiogenesis in fluorescent transgenic Zebrafish <ce:italic>in vivo</ce:italic> model. Interestingly, <ce:bold>14</ce:bold> demonstrated less toxicity and was more potent, as compared to sunitinib [<ce:cross-ref id="crosref0170" refid="bib26">26</ce:cross-ref>].</ce:para>
                     <ce:para id="p0360" view="all">Nintedanib, a 3-alkenyl oxindole derivative is a potent tyrosine kinase inhibitor [<ce:cross-ref id="crosref0175" refid="bib7a">7a</ce:cross-ref>]. It exerts antiproliferative action <ce:italic>via</ce:italic> targeting VEGF, PDGF and FGF receptors. To discover more potent and selective multi-kinase inhibitors with superior antitumour activity, Hou’s group reported conformationally constraint nintedanib derivatives by incorporating pyrrole Mannich base moiety. Compound <ce:bold>15</ce:bold> showed VEGFR-2 and PDGFRβ inhibition with IC<ce:inf loc="post">50</ce:inf> values of 82.3 nM and 11 nM, respectively. Later, the same research group demonstrated the structural modifications in the pyrrole ring and ring A of nintedanib which led to the change in dihedral angle between aforementioned rings resulting in the significant anti-kinase activity (<ce:cross-ref id="crosref0180" refid="fig7">Fig. 7</ce:cross-ref>
                        <ce:float-anchor refid="fig7"/></ce:float-anchor>). These slight modifications led to the identification of compound <ce:bold>16</ce:bold> as potent VEGFR-2 and PDGFRβ inhibitor with IC<ce:inf loc="post">50</ce:inf> values of 6.5 and 9.9 nM, respectively, which were prepared by introduction of methyl group on the pyrrole ring. Further investigation revealed that compound <ce:bold>16</ce:bold> strongly inhibited varied kinases, such as VEGFR-1 and 3, PDGFRα, c-KIT kinase etc. Moreover, compound <ce:bold>16</ce:bold> dose-dependently and efficaciously inhibited/supressed phosphorylation of AKT and ERK. In addition, it also inhibited the colony formation and induced apoptosis in HT-29, MKN74, and HepG2 cancer cell lines. The SAR for compound 16 is discussed in <ce:cross-ref id="crosref0185" refid="fig7">Fig. 7</ce:cross-ref> [<ce:cross-ref id="crosref0190" refid="bib27">27</ce:cross-ref>,<ce:cross-ref id="crosref0195" refid="bib28">28</ce:cross-ref>].</ce:para>
                     <ce:para id="p0365" view="all">In 2018, Eldehna et al., reported synthesis of spirooxindole derivatives <ce:bold>17a</ce:bold> and <ce:bold>17b</ce:bold> 
                        <ce:italic>via</ce:italic> a one-pot three-component reaction having potent EGFR inhibition with IC<ce:inf loc="post">50</ce:inf> of 120 nM and 150 nM, respectively (<ce:cross-ref id="crosref0200" refid="fig8">Fig. 8</ce:cross-ref>
                        <ce:float-anchor refid="fig8"/></ce:float-anchor>). These compounds also revealed reasonable <ce:italic>in vitro</ce:italic> antiproliferative activity against MDA-MB-231 (breast) cancer cell line with IC<ce:inf loc="post">50</ce:inf> of 6.40 μM (<ce:bold>17a</ce:bold>) and 6.70 μM (<ce:bold>17b</ce:bold>) and no significant toxicity against normal human lung fibroblast cell line (WI38). Mechanistic investigation revealed that compound <ce:bold>17a</ce:bold> triggered apoptosis in MDA-MB-231 cells as revealed by multi-fold rise in the levels of pro-apoptotic proteins caspase-3 and bax and downregulation of antiapoptotic protein Bcl-2 as compared to the control. Moreover, compound <ce:bold>17a</ce:bold> also induced cell cycle arrest at G2-M phase and also caused significant increase in the annexin-V- FITC bound cells [<ce:cross-ref id="crosref0205" refid="bib29">29</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0050">Cyclin-dependent kinase (CDK) inhibitors</ce:section-title>
                     <ce:para id="p0370" view="all">Cyclin-dependent kinases (CDKs) are Ser/Thr kinases and play a major role in controlling cell growth and regulation. Activation of CDKs takes place by complex formation between cyclin and a CDK [<ce:cross-ref id="crosref0210" refid="bib30">30</ce:cross-ref>]. These complexes phosphorylate and inactivate the retinoblastoma protein (pRb), causing the release of the E2F and DP1 transcription factors, which regulate the gene expression required for G1/S transition [<ce:cross-ref id="crosref0215" refid="bib31">31</ce:cross-ref>]. Therefore, inhibition of CDKs halts cell cycle progression.</ce:para>
                     <ce:para id="p0375" view="all">Chiou et al., realized the anticancer potential of naturally-derived meisoindigo derivatives and subsequently synthesized ring-opening analogues of meisoindigo possessing CDK inhibitory activity [<ce:cross-ref id="crosref0220" refid="bib32">32</ce:cross-ref>]. Particularly, compound <ce:bold>18b</ce:bold> with <ce:italic>p</ce:italic>-chlorobenzyl substitution demonstrated potent anticancer activity with an IC<ce:inf loc="post">50</ce:inf> of 0.4 μM against NCI-H460 cell line. The cytotoxicity was significantly affected by the electronic nature of substitutions on various positions of 3-ylideneoxindole acetamides (<ce:cross-ref id="crosref0225" refid="fig9">Fig. 9</ce:cross-ref>
                        <ce:float-anchor refid="fig9"/></ce:float-anchor>). 5-methoxy group along with N-<ce:italic>p-</ce:italic>chlorobenzyl substitution on oxindole ensured significant cytotoxicity compared to bromo substituent. Substitution of heterocyclic ring like 3-methylisoxazolyl at R<ce:sup loc="post">2</ce:sup> position of 3-ylideneoxindole acetamides has also shown best results. Furthermore, the presence of heteroaryl groups 6-quinolinyl at the R<ce:sup loc="post">3</ce:sup> position showed potent activity against NCI-H460 cell lines. Flow cytometry analysis showed a significant increase in the subG1 population up to 40% and arrested cell cycle in G1 phase. Western blot study demonstrated a transitory rise in the levels of cyclin E followed by reduction in retinoblastoma phosphorylation. Caspase activity assay showed significant increase in the activity of pro-apoptotic caspases (caspase-3, -8, -9). Caspase-mediated cleavage of PARP-1 in a time-dependent manner was confirmed by western-blotting which is responsible for various cellular processes, including modulation of chromatin structure, transcription, replication, recombination, and DNA repair [<ce:cross-ref id="crosref0230" refid="bib33">33</ce:cross-ref>]. Molecular docking studies revealed that the carbonyl group of the oxindole ring in compound <ce:bold>18a</ce:bold> forms hydrogen bonds with two residues (Gly15 and Lys35) and amide group of 6-quinolinyl moiety forms a hydrogen bond with ASP97 in the binding pocket of CDK 4. <ce:italic>In vivo</ce:italic> studies were performed on CT26-xenografted BALB/c mouse model. Compound <ce:bold>18a</ce:bold> caused significant reduction in the size of tumour without loss of body weight when administered intraperitoneally.</ce:para>
                     <ce:para id="p0380" view="all">In the search for potent CDK4 inhibitors, Warhi et al.[<ce:cross-ref id="crosref0235" refid="bib34">34</ce:cross-ref>], employed the concept of molecular hybridization [<ce:cross-refs id="crosrefs0045" refid="bib35 bib35a">35</ce:cross-refs>] to design oxindole-indole conjugates. The results obtained from CDK4 kinase inhibition assay demonstrated that compound <ce:bold>19a</ce:bold> inhibited CDK4 enzyme with IC<ce:inf loc="post">50</ce:inf> value of 1.26 μM. The screening results of the target compounds for the inhibition of various isoforms of CDK enzyme (CDK2, CDK4 and CDK9) showed good to weak inhibition of CDK2 and CDK4, whereas it demonstrated weak potency against CDK9 isoform. The results of <ce:italic>in vitro</ce:italic> studies revealed that the synthesized hybrids exhibited significant antitumour property with IC<ce:inf loc="post">50</ce:inf> values ranging from 0.39 ± 0.05 to 67.51 ± 3.02 μM against human breast cancer cell lines (MDA-MB-231 and MCF-7). SAR-analysis suggested that substitution at C5 position of oxindole with methyl, methoxy, chloro and substitution at <ce:italic>N</ce:italic>1 of oxindole with <ce:italic>p</ce:italic>-fluorobenzyl group showed maximum antiproliferative activity. The most active compounds <ce:bold>19a</ce:bold> and <ce:bold>19b</ce:bold> arrested cell cycle in G0/G1 phase and induced apoptosis in MCF7 cell lines. The results of molecular docking study of <ce:bold>19a</ce:bold> are displayed in <ce:cross-ref id="crosref0240" refid="fig10">Fig. 10</ce:cross-ref>
                        <ce:float-anchor refid="fig10"/></ce:float-anchor>.</ce:para>
                     <ce:para id="p0385" view="all">Likewise, the same research group also synthesized <ce:italic>N</ce:italic>-alkylindole-isatin conjugates as CDK2 inhibitors [<ce:cross-ref id="crosref0245" refid="bib36">36</ce:cross-ref>]. Compound <ce:bold>20</ce:bold> showed prominent CDK2 inhibitory activity with an IC<ce:inf loc="post">50</ce:inf> value of 0.85 ± 0.03 μM. In addition, it showed noteworthy inhibitory activity on anti-apoptotic Bcl-2 protein (IC<ce:inf loc="post">50</ce:inf> = 0.46 ± 0.02 μM) (<ce:cross-ref id="crosref0250" refid="fig10">Fig. 10</ce:cross-ref>). The cytotoxic evaluation demonstrated that compound <ce:bold>20</ce:bold> showed promising anticancer activity with IC<ce:inf loc="post">50</ce:inf> values of 2.6 ± 0.17 μM, 4.7 ± 0.28 μM and 7.3 ± 0.42 μM against HCT-116, MDA-MB-231 and A549 human cancer cell lines, respectively. The substitution of <ce:italic>N</ce:italic>-propyl group on indole showed important hydrophobic interactions in the active pocket of CDK2 and Bcl-2 proteins.</ce:para>
                     <ce:para id="p0390" view="all">Recently, Eldehna et al., reported oxindole/benzofuran hybrids utilising amido and ureido linkers as dual CDK2/GSK-3β inhibitors [<ce:cross-ref id="crosref0255" refid="bib37">37</ce:cross-ref>]. The most promising hybrids <ce:bold>21a</ce:bold> and <ce:bold>21c</ce:bold> potently inhibited CDK-2 with IC<ce:inf loc="post">50</ce:inf> values of 38 nM and 53 nM, respectively and GSK-3β with IC<ce:inf loc="post">50</ce:inf> values of 32.09 and 40.13 nM, respectively (<ce:cross-ref id="crosref0260" refid="fig11">Fig. 11</ce:cross-ref>
                        <ce:float-anchor refid="fig11"/></ce:float-anchor>). As compared to the reference standard staurosporine, compounds <ce:bold>21a</ce:bold>, <ce:bold>21b</ce:bold> and <ce:bold>21c</ce:bold> showed remarkable cytotoxicity with IC<ce:inf loc="post">50</ce:inf> values of 3.41, 3.45 and 2.27 μM against MCF-7 cell lines, respectively and IC<ce:inf loc="post">50</ce:inf> values of 3.82, 4.53 and 7.80 μM against T-47D cell line, respectively. Mechanistically, compounds <ce:bold>21a</ce:bold>–<ce:bold>c</ce:bold> halted cell cycle at G2/M phase thereby inducing apoptosis in MCF-7 cell lines while, it showed no significant toxicity against normal breast epithelial cells (MCF-10A). Molecular docking study predicted the binding mode of hybrid in the active site of CDK2 and GSK-3β and the interactions as shown in <ce:cross-ref id="crosref0265" refid="fig11">Fig. 11</ce:cross-ref>.</ce:para>
                     <ce:para id="p0395" view="all">3,3-spirocyclic oxindoles exist in many bioactive natural products also exhibit potent CDK inhibitory activity. Kamal and co-workers in 2016 reported catalyst-free synthesis of 5′<ce:italic>H</ce:italic>-spiro[indoline-3,4′-pyrrolo[1,2-<ce:italic>a</ce:italic>]quinoxalin]-2-ones derivatives <ce:bold>22</ce:bold> from isatin and 2-(1<ce:italic>H</ce:italic>-pyrrol-1-yl)aniline. MTT assay indicated that compound <ce:bold>22</ce:bold> showed impressive cytotoxic activity with an IC<ce:inf loc="post">50</ce:inf> values of 1.16 and 1.63 μM on human prostate (DU145) and colon (HT-29) cancer cell lines, respectively. Cell cycle arrest in G0/G1 phase at 1 μM concentration and drop in mitochondrial membrane potential revealed apoptotic induction in DU145 cells. Furthermore, Western blot analysis exhibited an increased expression of cell cycle proteins p-21 and p-27 and down-regulation of CDK4 enzyme. Molecular docking analysis also unveiled the possible modes of interaction with an active pocket of CDK4 (<ce:cross-ref id="crosref0270" refid="fig12">Fig. 12</ce:cross-ref>
                        <ce:float-anchor refid="fig12"/></ce:float-anchor>) [<ce:cross-ref id="crosref0275" refid="bib38">38</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0055">p21-activated protein kinase 4 (PAK4) inibitors</ce:section-title>
                     <ce:para id="p0400" view="all">p21-Activated kinase (PAK) functions play crucial role in various cellular activities, such as cell proliferation, migration and survival. Depending on their structures and roles, they are categorised as group I (PAK1 – 3) and group II (PAK4 – 6). Role of PAK4 is well-known in the cancer progression by hastening epithelial–mesenchymal transition, invasion, and metastasis. Thus, PAK4 is contemplated as an important molecular target for anticancer drug therapy [<ce:cross-ref id="crosref0280" refid="bib39">39</ce:cross-ref>].</ce:para>
                     <ce:para id="p0405" view="all">PF-3758309, bearing pyrrolopyrazole scaffold was identified as a potent PAK4 inhibitor (K<ce:inf loc="post">d</ce:inf> = 2.7 nM) which act by blocking phosphorylation of the PAK4 substrate GEF-H1 with IC<ce:inf loc="post">50</ce:inf> 1.3 nM and anchorage-independent growth of the cancer cells. Particularly, it inhibited PAK4-dependent pathways thereby regulating essential activities related to cell proliferation and survival [<ce:cross-ref id="crosref0285" refid="bib40">40</ce:cross-ref>]. Revelations from previous literature with regard to inhibitory effect of PF-3758309 at ATP binding site of PAKs and selectivity of sunitinib for type-II PAKs over type-I PAKs prompted Guo and co-workers to hybridize the pharmacophores of the two molecules to design novel indolin-2-one derivatives <ce:bold>24</ce:bold> and <ce:bold>25</ce:bold>. The research group speculated that further substitution of D/L-phenylglycinol at C5 position of sunitinib will allow certain interactions with ribose pocket and P-loop and would enhance the potency (<ce:cross-ref id="crosref0290" refid="fig13">Fig. 13</ce:cross-ref>
                        <ce:float-anchor refid="fig13"/></ce:float-anchor>). As a result, compounds <ce:bold>24a–c</ce:bold> displayed prominent PAK4 inhibition as represented in <ce:cross-ref id="crosref0295" refid="fig14">Fig. 14</ce:cross-ref>
                        <ce:float-anchor refid="fig14"/></ce:float-anchor>. Moreover, these compounds have shown significant antiproliferative potential on MCF-7 and A549 cell lines in which PAK4 kinase was found to be overexpressed (<ce:cross-ref id="crosref0300" refid="fig14">Fig. 14</ce:cross-ref>). Compound <ce:bold>24c</ce:bold> induced apoptosis and cell cycle arrest at G2/M phase in A549 cell line. Further study demonstrated antimetastatic potential of compound <ce:bold>24c</ce:bold> against A549 cell line which was confirmed by reduced phosphorylation of key proteins PAK4/LIMK1/cofilin involved in signalling pathway which has been correlated with cellular metastatic behaviour [<ce:cross-ref id="crosref0305" refid="bib41">41</ce:cross-ref>]. From SAR point of view, L-phenylglycinol substitution was the best fit for rigid PAK4 P-loop pocket size. Any substitution or change in the structure of L-phenylglycinol resulted in loss of PAK4 inhibition. Stereochemistry of compounds significantly affected PAK4 inhibitory activity, because <ce:italic>S-</ce:italic>enantiomer was 153-fold more potent than <ce:italic>R-</ce:italic>enantiomer. On the other hand, compound with imidazole moiety was more active than oxindoles bearing pyrrole ring (<ce:cross-ref id="crosref0310" refid="fig13">Fig. 13</ce:cross-ref>). The interaction of compound <ce:bold>24c</ce:bold> with ATP binding site of PAK4 kinase is shown in <ce:cross-ref id="crosref0315" refid="fig12">Fig. 12</ce:cross-ref>. Evaluation of various physicochemical parameters such as clogP, tPSA, LE, LLE, LELP revealed that all the values were within acceptable range for good drug-likeness of active molecules [<ce:cross-ref id="crosref0320" refid="bib42">42</ce:cross-ref>].</ce:para>
                     <ce:para id="p0410" view="all">Significant anticancer potential demonstrated by 3-heterocyclic-5-amide substituted indolin-2-one <ce:bold>24</ce:bold> in the preceding discovery, further led to structure guided modifications at C3-position of indolin-2-one core by Guo research group [<ce:cross-ref id="crosref0325" refid="bib43">43</ce:cross-ref>]. They introduced substituents at 4/5 position of imidazole and C3 alkene of indolin-2-one scaffold to access the lower hinge region and hydrophobic region of the PAK4 enzyme. Results of enzyme inhibition assay revealed that compounds <ce:bold>25a</ce:bold>–<ce:bold>f</ce:bold> showed excellent to modest inhibitory potential (<ce:cross-ref id="crosref0330" refid="fig15">Fig. 15</ce:cross-ref>
                        <ce:float-anchor refid="fig15"/></ce:float-anchor>). The screened compounds were also assessed for antitumour activity against A549 and HCT116 human cancer cell lines where compound <ce:bold>25a</ce:bold>, <ce:bold>25c</ce:bold>–<ce:bold>f</ce:bold> showed significant antiproliferative activity in sub-micromolar range. X-ray crystallography study confirmed that 3-substituted-indolin-2-one scaffold of compound <ce:bold>25a</ce:bold> formed hydrogen bond with Glu396 and Leu398. Further study demonstrated hydrogen bond formation by the oxygen of the amide group with Lys350 and Asp458. High potency against PAK4 has been attributed to the phenyl group attached to the alkene enclosed in lipophilic cleft (<ce:cross-ref id="crosref0335" refid="fig15">Fig. 15</ce:cross-ref>). ADMET and drug-likeliness properties (calculated <ce:italic>in silico</ce:italic>) were found to fall in the desirable range.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.4" view="all">
                     <ce:label>2.4</ce:label>
                     <ce:section-title id="sectitle0060">Protein kinase B (Akt) inhibitors</ce:section-title>
                     <ce:para id="p0415" view="all">Protein kinase B (Akt) acts as nodal point for transduction of extracellular as well as intracellular oncogenic signals. Akt pathway has been found to be altered in numerous human malignancies. Therefore, targeting Akt signalling pathway results in apoptosis and growth inhibition of tumour cells [<ce:cross-ref id="crosref0340" refid="bib44">44</ce:cross-ref>].</ce:para>
                     <ce:para id="p0420" view="all">Nagarsenkar et al., reported triazole-linked oxindole glycoconjugates, having significant anticancer profile. Compound <ce:bold>26</ce:bold> showed reasonable cytotoxic activity with IC<ce:inf loc="post">50</ce:inf> of 9.3 ± 0.5 μM on DU-145 cells (<ce:cross-ref id="crosref0345" refid="fig16">Fig. 16</ce:cross-ref>
                        <ce:float-anchor refid="fig16"/></ce:float-anchor>). The SAR study indicated that the activity of compound was dependent on the type of substituent at C3-position of oxindole and <ce:italic>E</ce:italic>/<ce:italic>Z</ce:italic>-configuration of the molecules. The general SAR is as follows-a) The inhibitory effect was enhanced selectively towards DU145 cell line in case of tolyl substitution at C3-position of oxindole (both <ce:italic>E</ce:italic> and <ce:italic>Z</ce:italic> isomers), while no activity was observed against MCF-7 cell lines; b) Oxindole glycoconjugate substituted with 4-(dimethylamino)phenyl group (both <ce:italic>E</ce:italic> and <ce:italic>Z</ce:italic>) also showed excellent activity against all the tested cancer cell lines (<ce:italic>E-</ce:italic>isomer: 11.2 ± 0.9 μM; Z-isomer: 10.1 ± 0.03 μM on DU145 cells); c) Oxindole bearing furyl substitution with <ce:italic>E</ce:italic>-configuration was more active than its respective <ce:italic>Z-</ce:italic>isomers. However, it showed significant toxicity towards non-cancerous cell lines; d) On the other hand, alkyl substituted compounds with <ce:italic>E</ce:italic>-configuration showed more cytotoxicity than <ce:italic>Z</ce:italic>-isomers. Further, the colony formation assay reveals that compound <ce:bold>26</ce:bold> inhibited growth and proliferation of the prostate cancer cells (DU145) at 10 μM concentration. Moreover, <ce:bold>26</ce:bold> also caused cell cycle arrest in sub-G1 phase. The caspase activation was studied in DU-145 cells which demonstrated that compound <ce:bold>26</ce:bold> activated caspase 3 inducing apoptosis. It was shown that the compound <ce:bold>26</ce:bold> was responsible for targeting the Akt pathway as phosphorylation of Akt in DU-145 cells was significantly reduced by the treatment of compound <ce:bold>26</ce:bold> [<ce:cross-ref id="crosref0350" refid="bib45">45</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.5" view="all">
                     <ce:label>2.5</ce:label>
                     <ce:section-title id="sectitle0065">Microtubule affinity regulating kinase 4 (MARK4) inhibitors</ce:section-title>
                     <ce:para id="p0425" view="all">Microtubule affinity regulating kinases (MARKs) are highly conserved serine/threonine kinases and a member of subfamily adenosine-monophosphate activated protein kinase (AMPK) which is expressed throughout human body with highest concentrations found in testis and brain. MARK4 regulates microtubule dynamics by phosphorylating microtubule-associated proteins (MAP) which causes detachment of MAPs from microtubules. MARKs regulate several other functions, such as interfering with signal transduction, adipogenesis, cell polarity, cell cycle progression and positioning of organelle [<ce:cross-ref id="crosref0355" refid="bib46">46</ce:cross-ref>].</ce:para>
                     <ce:para id="p0430" view="all">Aneja’s group has explored the synthesis and anticancer activity of isatin-triazole-hydrazone hybrids <ce:bold>27</ce:bold>. Initially performed docking studies indicate the binding of isatin-triazole scaffolds in the active site of MARK4, with considerable binding interactions (<ce:cross-ref id="crosref0360" refid="fig17">Fig. 17</ce:cross-ref>
                        <ce:float-anchor refid="fig17"/></ce:float-anchor>). Compound <ce:bold>27</ce:bold> showed potent and selective inhibition towards MARK4 (IC<ce:inf loc="post">50</ce:inf> 1.54 μM). The screened compound <ce:bold>27</ce:bold> showed modest antiproliferative activity against HepG2, MDA-MB-435s and MCF-7 cell lines with IC<ce:inf loc="post">50</ce:inf> values of 8.14 μM, 9.94 μM, and 6.22 μM, respectively. SAR study revealed the substitution of electron-donating group at C5/C7 position of indolinone scaffold enhanced the enzyme inhibition and antiproliferative potential of the derivatives while substitution with electron-withdrawing halogen atoms decreased the potency (<ce:cross-ref id="crosref0365" refid="fig17">Fig. 17</ce:cross-ref>). Mechanistic studies unveil compound <ce:bold>27</ce:bold> to cause apoptotic cell death in cancer cell lines, which might be the outcome of higher levels of ROS in the cells [<ce:cross-ref id="crosref0370" refid="bib47">47</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.6" view="all">
                     <ce:label>2.6</ce:label>
                     <ce:section-title id="sectitle0070">Polo-like kinase (PLK4) inhibitors</ce:section-title>
                     <ce:para id="p0435" view="all">Serine/threonine kinases, such as Cyclin dependent kinase (Cdk), Polo-like kinase (PLK) and Aurora kinase are the three major regulators of cell cycle and play a key role in orchestration of M-phase events. All the PLKs (PLK1-4) except PLK5 are mainly involved in the formation of bipolar spindle, anaphase-promoting complex amid mitotic exit and cleavage structure during cytokinesis, centrosome duplication, and chromosome segregation. Hyperactivation of PLK4 promotes centrosome amplification bringing about chromosomal instability and aneuploidy, consequently leading to tumorigenesis [<ce:cross-ref id="crosref0375" refid="bib48">48</ce:cross-ref>,<ce:cross-ref id="crosref0380" refid="bib49">49</ce:cross-ref>].</ce:para>
                     <ce:para id="p0440" view="all">Notable reduction in cell proliferation due to depletion of PLK4 by siRNA and anticancer activity demonstrated by several other small molecule PLK4 inhibitors fostered further screening of compounds for the identification of novel PLK4 inhibitors [<ce:cross-ref id="crosref0385" refid="bib50">50</ce:cross-ref>]. 4-Hydroxybenzylideneindolin-2-one <ce:bold>28</ce:bold> was identified as an initial hit from virtual screening using homology model. Further, based on this hit, the PLK4 inhibitor <ce:bold>29</ce:bold> was designed by morphing phenol moiety into its heterocyclic bioisoster like indazole. Replacing phenol with indazole led to strong hydrogen-bonding interactions with Glu90 and Cys92 in the hinge region. This newly designed (<ce:italic>E</ce:italic>)-3-((1<ce:italic>H</ce:italic>-indazol-6-yl)methylene)indolin-2-one <ce:bold>29</ce:bold> showed PLK4 inhibition with IC<ce:inf loc="post">50</ce:inf> of 0.29 μM. Further optimization of <ce:bold>29</ce:bold> for potent PLK4 inhibition furnished compound <ce:bold>30</ce:bold> showing IC<ce:inf loc="post">50</ce:inf> 0.6 nM (<ce:cross-ref id="crosref0390" refid="fig18">Fig. 18</ce:cross-ref>
                        <ce:float-anchor refid="fig18"/></ce:float-anchor>) [<ce:cross-ref id="crosref0395" refid="bib51">51</ce:cross-ref>].</ce:para>
                     <ce:para id="p0445" view="all">Next, efforts were taken by Pauls’s group in 2014 to discover more potent PLK4 inhibitors, which led to the identification of configurationally stable 2-(1<ce:italic>H</ce:italic>-indazol-6-yl)spiro[cyclopropane-1,3′-indolin]-2′-one derivatives <ce:bold>31</ce:bold>. The research group bioisosterically replaced alkene linker in compound <ce:bold>30</ce:bold> with spiro-cyclopropane leading to significant improvement in physicochemical and pharmacokinetic properties and showed comparable affinity towards PLK4, as compared to compound <ce:bold>30</ce:bold> [<ce:cross-ref id="crosref0400" refid="bib52">52</ce:cross-ref>]. Later, the same research group developed chiral synthetic route for asymmetric synthesis of spirocyclopropyl oxindole derivatives by double S<ce:inf loc="post">
                           <ce:italic>N</ce:italic>
                        </ce:inf>2 displacement of a chiral <ce:italic>bis</ce:italic>-electrophile with <ce:italic>bis</ce:italic>-nucleophile. From the results of <ce:italic>in vitro</ce:italic> assays, it was evident that stereochemistry had dramatic influence on the PLK4 inhibition and growth inhibition of breast cancer cell lines, as 1<ce:italic>R</ce:italic>,2<ce:italic>S</ce:italic> enantiomers of compound <ce:bold>31</ce:bold> and <ce:bold>32</ce:bold> were more potent than 1<ce:italic>S</ce:italic>,2<ce:italic>R</ce:italic> enantiomer and the racemate (<ce:cross-ref id="crosref0405" refid="fig19">Fig. 19</ce:cross-ref>
                        <ce:float-anchor refid="fig19"/></ce:float-anchor>). SAR studies were performed and displayed in <ce:cross-ref id="crosref0410" refid="fig20">Fig. 20</ce:cross-ref>
                        <ce:float-anchor refid="fig20"/></ce:float-anchor>. Thorough lead optimization studies revealed that, inclusion of morpholine ring reduced the <ce:italic>p</ce:italic>Ka of benzylic nitrogen from 8.9 to 7.1 leading to the enhanced permeability and overall pharmacokinetic profile. Moreover, the methoxy substitution on oxindole ring aided in improving potency and selectivity towards PLK4. Compound <ce:bold>33</ce:bold> with superior bioavailability effectively inhibited growth of various breast cancer cells like MDA-MB-468, MCF-7, HCC-1954 with GI<ce:inf loc="post">50</ce:inf> value of 6, 8 and 5 nM, respectively. Additionally, it also exhibited favourable binding against PLK4 (K<ce:inf loc="post">i</ce:inf> 0.26 ± 0.10 nM) and showed a magnitude higher selectivity against PLK4 (EC<ce:inf loc="post">50</ce:inf> 12 nM) than the other tested kinases. In mouse xenograft studies, compound <ce:bold>33</ce:bold> exerted 98% tumour growth inhibition at 39 mg/kg (on the 25th day) against HCT116 xenograft model and the doses were well tolerated. Presently, the compound <ce:bold>33</ce:bold> (identified as CFI-400945) is under clinical development (phase II clinical trials) [<ce:cross-ref id="crosref0415" refid="bib53">53</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.7" view="all">
                     <ce:label>2.7</ce:label>
                     <ce:section-title id="sectitle0075">PIM1 kinase inhibitors</ce:section-title>
                     <ce:para id="p0450" view="all">PIM (pro-viral integration site for Moloney murine leukaemia virus) kinases triggers transcription of genes implicated in cell proliferation promoting cell survival. Janus kinase/signal transducers and activators of transcriptions (JAK/STATs) are the upstream target proteins of PIM which upon activation causes stimulation of PIM kinase. These kinases regulate activity of downstream signalling targets through phosphorylation of transcription factor (myelocytomatosis) MYC, cell cycle modulators such as p21<ce:sup loc="post">cip1/Waf1</ce:sup> and p27<ce:sup loc="post">kip1</ce:sup>, BCL-2 associated agonist of cell death (BAD) causing regulation of gene transcription, cell cycle progression and apoptosis. Overexpression of PIM1 has been observed in several cancers including prostate, pancreatic, colon, chronic lymphocytic leukaemia, non-Hodgkin’s lymphoma, and multiple myeloma [<ce:cross-ref id="crosref0420" refid="bib54">54</ce:cross-ref>,<ce:cross-ref id="crosref0425" refid="bib55">55</ce:cross-ref>].</ce:para>
                     <ce:para id="p0455" view="all">Sun et al., reported fused oxindoles with α,β-unsaturated ketones affording 3-alkylidene oxindoles as PIM1 kinase inhibitors. Compound <ce:bold>34</ce:bold> having the structural framework required for kinase inhibition showed selective anti PIM1 kinase activity with IC<ce:inf loc="post">50</ce:inf> of 5 μM. Initial screening of derivatives for their cytotoxic activity revealed compound <ce:bold>34</ce:bold> with IC<ce:inf loc="post">50</ce:inf> of 0.13, 1.53, 2.02 μM against SW620, HeLa, and A549 cancer cells, respectively. It was noted that, <ce:italic>para-</ce:italic>substitution on phenyl ring exerted significant antiproliferative activity (on HeLa cancer cells) than <ce:italic>ortho- or meta-</ce:italic>substituents. Hydrogen-bonding, hydrophobic and halogen-bonding interactions were observed between active compound and active ATP binding site of PIM1 kinase through molecular simulation study (<ce:cross-ref id="crosref0430" refid="fig21">Fig. 21</ce:cross-ref>
                        <ce:float-anchor refid="fig21"/></ce:float-anchor>). Moreover, the compound <ce:bold>34</ce:bold> exhibited cell cycle arrest during DNA replication (at G<ce:inf loc="post">2</ce:inf>/M phase) and also induced apoptosis [<ce:cross-ref id="crosref0435" refid="bib56">56</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.8" view="all">
                     <ce:label>2.8</ce:label>
                     <ce:section-title id="sectitle0080">PDK1 inhibitors</ce:section-title>
                     <ce:para id="p0460" view="all">3-Phosphoinositide-dependent kinase 1 (PDK1) is a Ser/Thr kinase that phosphorylates many kinases such as protein kinase A, B (Akt), C (PKC), G, PKC-related kinases (PRK1 and PRK2), p70 ribobsomalS6-kinase (S6K1) along with serum and glucocorticoid-regulated kinase (SGK). PDK1 causes phosphorylation of Thr308 residue on the activation loop of Akt (T-loop) and aids in formation of the enzyme conformation with catalytic activity. Elevated levels of activated Akt have been observed in various cancers such as melanoma, breast, lung, gastric, prostate, haematological, and ovarian cancers. Activation of Akt in cancer cells stimulates tumour cell proliferation, metabolism, angiogenesis and suppresses apoptosis. Thus, PDK1/Akt signalling pathway might represent a promising target for the effective treatment of cancer [<ce:cross-ref id="crosref0440" refid="bib57">57</ce:cross-ref>].</ce:para>
                     <ce:para id="p0465" view="all">Glioblastoma multiforme (GBM) is one of the most common forms of CNS malignancies. The current therapeutic strategy remains to be ineffective due to the involvement of cancer stem cells (CSCs) in GBM. The CSCs are thought to help in cancer recurrence and were also found to promote resistance towards chemotherapy due to autorenewal properties. To develop more effective and targeted therapeutic molecules for GBM, understanding the underlying molecular mechanism is important. Previous studies have suggested hyperactivation of PI3K/AKT pathway to be major pathological pathway responsible for the malignant and resistant phenotype in GBM [<ce:cross-ref id="crosref0445" refid="bib58">58</ce:cross-ref>].</ce:para>
                     <ce:para id="p0470" view="all">Sestito et al., investigated the influence of diverse substituents at C5 position of oxindole towards inhibition of PDK1/Akt kinases. The results of SAR study are shown in <ce:cross-ref id="crosref0450" refid="fig22">Fig. 22</ce:cross-ref>
                        <ce:float-anchor refid="fig22"/></ce:float-anchor>. The synthesized derivatives of compound <ce:bold>35</ce:bold> significantly reduced the ASPC1 cell viability. Compound <ce:bold>35a</ce:bold> and <ce:bold>35c</ce:bold> have demonstrated sub-micromolar potency against PDK1 (IC<ce:inf loc="post">50</ce:inf> 0.98 and 0.31 μM, respectively). Compound <ce:bold>35a</ce:bold> remarkably inhibited proliferation of GBM cell lines ANGM-CSS and U-118MG with GI<ce:inf loc="post">50</ce:inf> values 7.73 μM and 14.6 μM, respectively. Further kinase profiling assay was performed to identify the off-target effects of compound <ce:bold>35a</ce:bold> which revealed that compound <ce:bold>35a</ce:bold> along with PDK1 inhibition also exhibited sub-micromolar potency against CHK1, GSK3A and GSK3B [<ce:cross-ref id="crosref0455" refid="bib59">59</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.9" view="all">
                     <ce:label>2.9</ce:label>
                     <ce:section-title id="sectitle0085">Aurora kinase inhibitors</ce:section-title>
                     <ce:para id="p0475" view="all">Aurora kinases represent a family of highly conserved cell cycle regulated serine/threonine kinases which comprises of three members like Aurora A, Aurora B, and Aurora C. The activity and expression of these kinases is regulated by cell cycle and it spikes during mitosis (G2/M phase). These kinases orchestrate crucial mitotic processes which covers centrosome maturation, chromosome alignment, chromatid segregation, and cytokinesis. Aberrant expression of Aurora kinase has been observed in numerous malignancies like breast, colorectal, kidney, lung, prostrate, pancreas, ovaries and liver cancers [<ce:cross-ref id="crosref0460" refid="bib60">60</ce:cross-ref>].</ce:para>
                     <ce:para id="p0480" view="all">Xie et al., in 2012 identified (<ce:italic>E</ce:italic>)-3-((<ce:italic>E</ce:italic>)-4-(benzo[<ce:italic>d</ce:italic>] [<ce:cross-ref id="crosref0465" refid="bib1">1</ce:cross-ref>,<ce:cross-ref id="crosref0470" refid="bib3">3</ce:cross-ref>]dioxol-5-yl)-2-oxobut-3-en-1-ylidene)indolin-2-one (<ce:bold>36</ce:bold>) by virtual screening of their in-house compound library as Aurora B kinase inhibitor (<ce:cross-ref id="crosref0475" refid="fig23">Fig. 23</ce:cross-ref>
                        <ce:float-anchor refid="fig23"/></ce:float-anchor>). The compound <ce:bold>36</ce:bold> selectively suppressed Aurora B kinase by inhibiting the phosphorylation of ser10 on histone H3. The inhibition of Aurora B kinase induced apoptosis, cell cycle arrest (G2/M), and resulted in polyploidy cells. In addition, compound <ce:bold>36</ce:bold> also suppressed tumour growth <ce:italic>in vivo</ce:italic> in athymic nude mice. It also occupied the ATP binding site of Aurora kinase B by forming H-bond with Ala173 as indicated by molecular docking analysis [<ce:cross-ref id="crosref0480" refid="bib61">61</ce:cross-ref>].</ce:para>
                     <ce:para id="p0485" view="all">The Akt/PDK1 and Aurora kinase A signalling cascades play a vital role in GBM cell survival or migration and also promotes self-renewal of the GSCs. Daniele et al. identified a treatment strategy for GBM based on concurrent inhibition of Akt/PDK1 and Aurora A kinase. The study revealed that combination of MP7 (a selective inhibitor of Akt/PDK1 pathway) and alisertib (Aurora A kinase inhibitor) showed additive/synergic effect on inhibition of proliferation of GBM and GSC cells as compared to the single treatment cells. Based on these findings, the research group identified SA16 (<ce:bold>37</ce:bold>) as a dual inhibitor of Aurora A kinase and PDK1 with significant IC<ce:inf loc="post">50</ce:inf> 35 nM and 416 nM, respectively. SA16 displayed antiproliferative effect on GBM cells and its stem cells in a concentration dependent manner. In addition, SA16 also induced apoptosis and differentiation in GSCs. The molecular docking analysis revealed that ((<ce:italic>Z</ce:italic>)-3-((1<ce:italic>H</ce:italic>-imidazole-4-yl) methylene)indolin-2-one) part of <ce:bold>37</ce:bold> binds to the hinge region of Aurora A kinase by forming CH-π interactions as well as hydrophobic contacts. Further interactions of SA16 with active pocket of Aurora A kinase are represented in <ce:cross-ref id="crosref0485" refid="fig23">Fig. 23</ce:cross-ref> [<ce:cross-ref id="crosref0490" refid="bib62">62</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.10" view="all">
                     <ce:label>2.10</ce:label>
                     <ce:section-title id="sectitle0090">AMPK inhibitors</ce:section-title>
                     <ce:para id="p0490" view="all">The AMP activated kinase (AMPK) is a central metabolic sensor which regulates cellular metabolism and energy homeostasis. Overexpression of AMPK has been reported in various cancers which are resistant to energetic stress. Activated AMPK generates ATP by promoting numerous catabolic pathways in particular, glycolysis, fatty acid oxidation and mitochondrial biogenesis and assisting cancer cells to survive metabolic stress (hypoxia, glucose deprivation etc.) Therefore, inhibiting AMPK might result in fruitful antitumour effects by sensitizing cancer stem cells (CSCs) towards cytotoxic chemotherapy [<ce:cross-ref id="crosref0495" refid="bib63">63</ce:cross-ref>]. Matheson et al., designed a series of C5-substituted oxindoles as AMPK inhibitors. Compound <ce:bold>38a</ce:bold> showed higher inhibitory activity against both the isoforms of AMPK (α1 and α2) with IC<ce:inf loc="post">50</ce:inf> values of 93 ± 8 nM and 16.2 ± 7.4 nM, respectively as compared to the reference standard sunitinib. Further, SAR analysis showed that modification at 5th position of oxindole was well tolerated and may enhance selectivity for AMPK over RTK family. The results of SAR and molecular docking study are shown in <ce:cross-ref id="crosref0500" refid="fig24">Fig. 24</ce:cross-ref>
                        <ce:float-anchor refid="fig24"/></ce:float-anchor>. The cellular AMPK inhibition was evaluated by measuring the phosphorylation of AMPK substrate ACC (acetyl CoA carboxylase) by using ELISA assay in K562 cells. Compound <ce:bold>38b</ce:bold> and <ce:bold>38c</ce:bold> exhibited noticeably better reduction in <ce:italic>p</ce:italic>-ACC levels (23.7 and 29.2% of control respectively), as compared to sunitinib (51.8% of control). Interestingly, compound <ce:bold>38b</ce:bold> and <ce:bold>38c</ce:bold> selectively inhibited AMPK isoforms and showed reduced inhibition against RTK family receptors (VEGFR1, VEGFR2 and CSF1R) [<ce:cross-ref id="crosref0505" refid="bib64">64</ce:cross-ref>]. On the other hand, Bort et al., reported fluorinated 3,3-disubstituted oxindole derivatives as AMPK activators having cytotoxic potential [<ce:cross-ref id="crosref0510" refid="bib65">65</ce:cross-ref>].</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0095">Critical recap on oxindole based PKIs</ce:section-title>
                  <ce:para id="p0495" view="all">A closer eye on the structural features of various oxindole based derivatives suggests that functionalization at C3-position has provided diverse protein kinase inhibitors (<ce:cross-ref id="crosref0515" refid="fig25">Fig. 25</ce:cross-ref>
                     <ce:float-anchor refid="fig25"/></ce:float-anchor>). Especially, 3-alkenyl oxindole has showcased prominent anti-kinase activity. The 3-alkenyl bond is the most versatile position for substrate modification, favouring potential protein kinase inhibition. Furthermore, the configuration of 3-alkenyl oxindole is also important for activity, because <ce:italic>E-</ce:italic> and <ce:italic>Z-</ce:italic>isomers targets different protein kinases. Interestingly, bioisosteric replacement of double bond with cyclopropane revealed potent PLK4 inhibitory activity. Additionally, nature of substitution on oxindole ring in combination with 3-alkenyl bond has also significant impact on kinase activity. For example, <ce:italic>L</ce:italic>-phenylglycinol substitution on C5-position of oxindole resulted in PAK inhibition and substituting 5-hydroxyalkyl group favoured down regulation of AMPK.</ce:para>
                  <ce:para id="p0500" view="all">Similarly, 3-iminooxindoles and similar hydrazones have proven to be important leads with anti-kinase properties (as RTK, CDK, MARK4 inhibitors). It is observed that substitution with hydrophobic groups (for ex. OCH<ce:inf loc="post">3</ce:inf>) at C5-position of oxindole improves kinase inhibition potential. It should be noted that, free –NH on oxindole is essential in order to improve interaction of 3-alkenyl/imino oxindole with the target kinase protein. On the other hand, quaternary-centered spirooxindoles and 3,3-disubstituted oxindole remains less explored as PKIs. Only handful of examples are reported in the literature. The kinase inhibition activity substantially varies based upon heterocycle fused to spiro-centre. Moreover, <ce:cross-refs id="crosrefs0050" refid="tbl1 tbl2 tbl3">Tables 1–3</ce:cross-refs>
                     <ce:float-anchor refid="tbl1"/></ce:float-anchor>
                     <ce:float-anchor refid="tbl2"/></ce:float-anchor>
                     <ce:float-anchor refid="tbl3"/></ce:float-anchor> summarises various structures of 2-oxindole derivatives as PKIs, based on type of C3-functionalization.</ce:para>
               </ce:section>
               <ce:section id="sec4" role="conclusion" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0100">Conclusion</ce:section-title>
                  <ce:para id="p0505" view="all">Kinases regulate many essential functions by transferring the phosphate group from ATP onto diverse substrates. Since most of the cancers occur due to mutations and overexpression/deregulation of kinases, hence this enzyme class signifies important drug target for cancer. As a result, protein kinase inhibitors (PKIs) have paved way for the development of targeted therapeutics against tumorigenesis. Extensive research on oxindole based scaffolds confirms its multi-kinase inhibitory potential on various types of cancers. Diverse oxindole frameworks, such as 3-alkenyl oxindole, 3-iminooxindole, and spirooxindole have shown inhibitory potential on different kinases (RTK, CDK, PLK4, PAK4, AMPK, etc.). A characteristic feature of some oxindole derivatives, including sunitinib, is its ability to inhibit angiogenesis which is a crucial prognostic factor in many types of cancers. Furthermore, semaxinib (VEGFR inhibitor) and CFI-400945 (first potent PLK4 inhibitor) have made their way to clinical trials for the treatment of cancer. Nevertheless, developing oxindole-containing selective kinase inhibitors remains a challenging task in order to reduce off-target side effects. Overall, targeting kinases using oxindole derivatives posses some hurdles in kinase inhibitor research like achieving kinase selectivity, reducing off-target side effects and overcoming drug-resistance. Henceforth, the expedition on 2-oxindole derivatives as PKIs shall continue in the near future. This article delivers comprehensive information about the development of oxindole based motifs as small molecule kinase inhibitors.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0105">Declaration of competing interest</ce:section-title>
               <ce:para id="p0510" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0110">Acknowledgments</ce:section-title>
               <ce:para id="p0515" view="all">The authors are thankful to DoP, Ministry of Chemicals and Fertilizers, Govt. of India, New Delhi, for the award of NIPER fellowship. NIPER-H Research Communication No.: NIPER-H/2020/134.</ce:para>
            </ce:acknowledgment>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0115">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="bib1a">
                        <ce:label>a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.M.</ce:given-name>
                                 <ce:surname>Ferguson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Kinase inhibitors: the road ahead</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>353</sb:first-page>
                              <sb:last-page>376</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0015">F.M. Ferguson, N.S. Gray, Kinase inhibitors: the road ahead, Nat. Rev. Drug Discov. 17 (2018) 353-376;</ce:source-text>
                     <sb:reference id="bib1b">
                        <ce:label>b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rauch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Volinsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Romano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Kolch</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The secret life of kinases: functions beyond catalysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Commun. Signal.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>23</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0020">J. Rauch, N. Volinsky, D. Romano and W. Kolch, The secret life of kinases: functions beyond catalysis, Cell Commun. Signal. 9 (2011) 23.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Shapiro</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Next Generation Kinase Inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2020</sb:date>
                              <sb:publisher>
                                 <sb:name>Springer</sb:name>
                                 <sb:location>Cham</sb:location>
                              </sb:publisher>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">P. Shapiro, Next generation kinase inhibitors, Springer, Cham 2020.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Bhullar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.O.</ce:given-name>
                                 <ce:surname>Lagarón</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>McGowan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Parmar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.P.</ce:given-name>
                                 <ce:surname>Hubbard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.P.V.</ce:given-name>
                                 <ce:surname>Rupasinghe</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Kinase-targeted cancer therapies: progress, challenges and future directions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>48</sb:first-page>
                              <sb:last-page>67</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">K.S. Bhullar, N.O. Lagaron, E.M. McGowan, I. Parmar, A. Jha, B.P. Hubbard, H.P.V. Rupasinghe, Kinase-targeted cancer therapies: progress, challenges and future directions, Mol. Cancer 17 (2018) 48-67.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Cowan-Jacob</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Jahnke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Knapp</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Future Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>541</sb:first-page>
                              <sb:last-page>561</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">S.W. Cowan-Jacob, W. Jahnke and S. Knapp, Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases, Future Med. Chem. 6 (2014) 541-561.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Roskoski</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>152</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>104609</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">R. Roskoski Jr, Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update, Pharmacol. Res. 152 (2020) 104609.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="bib6a">
                        <ce:label>a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Niggula</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Vanjari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Thatikonda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Pooladanda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sridhar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Godugu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kamal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shankaraiah</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis of enamino-2-oxindoles <ce:italic>via</ce:italic> conjugate addition between α-azido ketones and 3-alkenyl oxindoles: cytotoxicity evaluation and apoptosis inducing studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3564</sb:first-page>
                              <sb:last-page>3573</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">P.K. Niggula, Y. Vanjari, S. Thatikonda, V. Pooladanda, P. Sharma, B. Sridhar, C. Godugu, A. Kamal, N. Shankaraiah, Synthesis of enamino-2-oxindoles via conjugate addition between α-azido ketones and 3-alkenyl oxindoles: cytotoxicity evaluation and apoptosis inducing studies, Bioorg. Med. Chem. Lett 28 (2018) 3564-3573;</ce:source-text>
                     <sb:reference id="bib6b">
                        <ce:label>b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Senwar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Thummuri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Bharghava</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.G.M.</ce:given-name>
                                 <ce:surname>Naidu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shankaraiah</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of 4′-<ce:italic>O</ce:italic>-alkylamino-tethered-benzylideneindolin-2-ones as potent cytotoxic and apoptosis inducing agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4061</sb:first-page>
                              <sb:last-page>4069</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">K.R. Senwar, T.S. Reddy, D. Thummuri, P. Sharma, S.K. Bharghava, V.G.M. Naidu, N. Shankaraiah, Design and synthesis of 4′-O-alkylamino-tethered-benzylideneindolin-2-ones as potent cytotoxic and apoptosis inducing agents, Bioorg. Med. Chem. Lett 26 (2016) 4061-4069;</ce:source-text>
                     <sb:reference id="bib6c">
                        <ce:label>c)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Senwar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Thummuri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.G.M.</ce:given-name>
                                 <ce:surname>Naidu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Srinivasulu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shankaraiah</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and apoptosis inducing effect of novel (<ce:italic>Z</ce:italic>)-3-(3′-methoxy-4′-(2-amino-2-oxoethoxy)-benzylidene) indolin-2-ones as potential antitumour agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem<ce:italic>.</ce:italic>
                                    </sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>118</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>34</sb:first-page>
                              <sb:last-page>46</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">K.R. Senwar, T.S. Reddy, D. Thummuri, P. Sharma, V.G.M. Naidu, G. Srinivasulu, N. Shankaraiah, Design, synthesis and apoptosis inducing effect of novel (Z)-3-(3′-methoxy-4′-(2-amino-2-oxoethoxy)-benzylidene) indolin-2-ones as potential antitumour agents, Eur. J. Med. Chem. 118 (2016) 34-46.</ce:source-text>
                     <sb:reference id="bib6d">
                        <ce:label>d)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.Q.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Spirooxindoles: promising scaffolds for anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>97</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>673</sb:first-page>
                              <sb:last-page>698</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">B. Yu, D.Q. Yu, H.M. Liu, Spirooxindoles: promising scaffolds for anticancer agents, Eur. J. Med. Chem. 97 (2015) 673-698.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="bib7a">
                        <ce:label>a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.J.</ce:given-name>
                                 <ce:surname>Roth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Binder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Colbatzky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Dallinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Schlenker-Herceg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Hilberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Wollin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kaiser</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Nintedanib: from discovery to the clinic</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1053</sb:first-page>
                              <sb:last-page>1063</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">G.J. Roth, R. Binder, F. Colbatzky, C. Dallinger, R. Schlenker-Herceg, F. Hilberg, S.L. Wollin, R. Kaiser, Nintedanib: from discovery to the clinic, J. Med. Chem. 58 (2015) 1053-1063;</ce:source-text>
                     <sb:reference id="bib5b">
                        <ce:label>b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.Q.M.</ce:given-name>
                                 <ce:surname>Chow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Eckhardt</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Sunitinib: from rational design to clinical efficacy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>884</sb:first-page>
                              <sb:last-page>889</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">L.Q.M. Chow, S.G. Eckhardt, Sunitinib: from rational design to clinical efficacy, J. Clin. Oncol. 25 (2007) 884-889.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Moon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.K.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and structure–activity relationships of novel indirubin derivatives as potent antiproliferative agents with CDK2 inhibitory activities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>237</sb:first-page>
                              <sb:last-page>246</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">M.J. Moon, S.K. Lee, J.W. Lee, W.K. Song, S.W. Kim, J.I. Kim, C. Cho, S.J. Choi and Y.C. Kim, Synthesis and structure-activity relationships of novel indirubin derivatives as potent antiproliferative agents with CDK2 inhibitory activities, Bioorg. Med. Chem. 14 (2006) 237-246.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="bib9a">
                        <ce:label>a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Sakla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kansal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shankaraiah</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Syntheses and reactivity of spiro-epoxy/aziridine oxindole cores: developments in the past decade</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Org. Biomol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8572</sb:first-page>
                              <sb:last-page>8596</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">A.P. Sakla, P. Kansal and N. Shankaraiah, Syntheses and reactivity of spiro-epoxy/aziridine oxindole cores: developments in the past decade, Org. Biomol. Chem.. 18 (2020) 8572-8596;</ce:source-text>
                     <sb:reference id="bib9b">
                        <ce:label>b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shankaraiah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Sakla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Laxmikeshav</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Tokala</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Reliability of click chemistry on drug discovery: a personal account</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rec.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>253</sb:first-page>
                              <sb:last-page>272</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">N. Shankaraiah, A.P. Sakla, K. Laxmikeshav, R. Tokala, Reliability of click chemistry on drug discovery: a personal account, Chem. Rec. 20 (2020) 253-272;</ce:source-text>
                     <sb:reference id="bib9c">
                        <ce:label>c)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Senwar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Jeengar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.G.M.</ce:given-name>
                                 <ce:surname>Naidu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kamal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shankaraiah</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>H<ce:inf loc="post">2</ce:inf>O-mediated isatin spiro-epoxide ring opening with NaCN: synthesis of novel 3-tetrazolylmethyl-3-hydroxy-oxindole hybrids and their anticancer evaluation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11</sb:first-page>
                              <sb:last-page>24</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">P. Sharma, K.R. Senwar, M.K. Jeengar, T.S. Reddy, V.G.M. Naidu, A. Kamal and N. Shankaraiah, H2O-mediated isatin spiro-epoxide ring opening with NaCN: synthesis of novel 3-tetrazolylmethyl-3-hydroxy-oxindole hybrids and their anticancer evaluation, Eur. J. Med. Chem. 104 (2015) 11-24;</ce:source-text>
                     <sb:reference id="bib9d">
                        <ce:label>d)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Senwar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nekkanti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sathish</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kamal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sridhar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shankaraiah</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A one-pot ‘click’ reaction from spiro-epoxides catalyzed by Cu(i)-pyrrolidinyl-oxazole-carboxamide</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>New J. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>39</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3973</sb:first-page>
                              <sb:last-page>3981</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">K.R. Senwar, P. Sharma, S. Nekkanti, M. Sathish, A. Kamal, B. Sridhar, N. Shankaraiah, A one-pot ‘click’ reaction from spiro-epoxides catalyzed by Cu(i)-pyrrolidinyl-oxazole-carboxamide, New J. Chem. 39 (2015) 3973-3981;</ce:source-text>
                     <sb:reference id="bib9e">
                        <ce:label>e)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.Y.</ce:given-name>
                                 <ce:surname>Desta</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Isatins as privileged molecules in design and synthesis of spiro-fused cyclic frameworks</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>112</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6104</sb:first-page>
                              <sb:last-page>6155</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">G.S. Singh, Z.Y. Desta, Isatins as privileged molecules in design and synthesis of spiro-fused cyclic frameworks, Chem. Rev. 112 (2012) 6104-6155.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Sampson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.K.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.T.</ce:given-name>
                                 <ce:surname>Forrest</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Edwards</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Laufer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Feher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ban</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Awrey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hodgson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Beletskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Mason</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kiarash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Green</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Mak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.W.</ce:given-name>
                                 <ce:surname>Pauls</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and optimization of (3-aryl-1<ce:italic>H</ce:italic>-indazol-6-yl) spiro [cyclopropane-1, 3′-indolin]-2′-ones as potent PLK4 inhibitors with oral antitumor efficacy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4625</sb:first-page>
                              <sb:last-page>4630</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">S.W. Li, Y. Liu, P.B. Sampson, N.K. Patel, B.T. Forrest, L. Edwards, R. Laufer, M. Feher, F. Ban, D.E. Awrey, R. Hodgson, I. Beletskaya, G. Mao, J.M. Mason, X. Wei, X. Luo, R. Kiarash, E. Green, T.W. Mak, G. Pan and H.W. Pauls, Design and optimization of (3-aryl-1H-indazol-6-yl) spiro [cyclopropane-1, 3′-indolin]-2′-ones as potent PLK4 inhibitors with oral antitumor efficacy, Bioorg. Med. Chem. Lett. 26 (2016) 4625-4630.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="bib11a">
                        <ce:label>a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sestito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Daniele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Nesi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Zappelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Di Maio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Marinelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Digiacomo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lapucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Martini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Novellino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rapposelli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Locking PDK1 in DFG-out conformation through 2-oxo-indole containing molecules: another tools to fight glioblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>118</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>47</sb:first-page>
                              <sb:last-page>63</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">S. Sestito, S. Daniele, G. Nesi, E. Zappelli, D. Di Maio, L. Marinelli, M. Digiacomo, A. Lapucci, C. Martini, E. Novellino and S. Rapposelli, Locking PDK1 in DFG-out conformation through 2-oxo-indole containing molecules: another tools to fight glioblastoma, Eur. J. Med. Chem. 118 (2016) 47-63;</ce:source-text>
                     <sb:reference id="bib11b">
                        <ce:label>b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Islam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bryant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.L.</ce:given-name>
                                 <ce:surname>Chou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Kochanny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.B.</ce:given-name>
                                 <ce:surname>Phillips</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Adler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Whitlow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Ho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Lentz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Polokoff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Subramanyam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.I.</ce:given-name>
                                 <ce:surname>Feldman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.O.</ce:given-name>
                                 <ce:surname>Arnaiz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3814</sb:first-page>
                              <sb:last-page>3818</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">I. Islam, J. Bryant, Y.L. Chou, M.J. Kochanny, W. Lee, G.B. Phillips, H. Yu, M. Adler, M. Whitlow, E. Ho, D. Lentz, M.A. Polokoff, B. Subramanyam, J.M. Wu, D. Zhu, R. I. Feldman and D.O. Arnaiz, Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity, Bioorg. Med. Chem. Lett 17 (2007) 3814-3818.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Noble</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Endicott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.N.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinase inhibitors: insights into drug design from structure</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>303</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1800</sb:first-page>
                              <sb:last-page>1805</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">M.E. Noble, J.A. Endicott and L.N. Johnson, Protein kinase inhibitors: insights into drug design from structure. Science 303 (2004) 1800-1805.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="bib13a">
                        <ce:label>a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hendrychová</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jorda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Kryštof</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>How selective are clinical CDK4/6 inhibitors?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Med. Res. Rev.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <ce:doi>10.1002/med.21769</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">D. Hendrychova, R. Jorda, V. Krystof, How selective are clinical CDK4/6 inhibitors? Med. Res. Rev. (2020) https://doi.org/10.1002/med.21769;</ce:source-text>
                     <sb:reference id="bib13b">
                        <ce:label>b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bhatia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Alam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Manaithiya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Alam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>Kahksha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Alam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Imran</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel quinazoline-based EGFR kinase inhibitors: a review focussing on SAR and molecular docking studies (2015–2019)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>204</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>112640</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">P. Bhatia, V. Sharma, O. Alam, A. Manaithiya, P. Alam, Kahksha, M.T. Alam and M. Imran, Novel quinazoline-based EGFR kinase inhibitors: a review focussing on SAR and molecular docking studies (2015-2019), Eur. J. Med. Chem. 204 (2020) 112640;</ce:source-text>
                     <sb:reference id="bib13c">
                        <ce:label>c)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.N.</ce:given-name>
                                 <ce:surname>Marak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Dowarah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Khiangte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.P.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A comprehensive insight on the recent development of cyclic dependent kinase inhibitors as anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>203</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>112571</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">B.N. Marak, J. Dowarah, D. Khiangte and V.P. Singh, A comprehensive insight on the recent development of cyclic dependent kinase inhibitors as anticancer agents, Eur. J. Med. Chem. 203 (2020) 112571;</ce:source-text>
                     <sb:reference id="bib13d">
                        <ce:label>d)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.T.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.G.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.M.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.P.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.H.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent advance in the development of novel, selective and potent FGFR inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>186</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>111884</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">F.T. Liu, N.G. Li, Y.M. Zhang, W.C. Xie, S.P. Yang, T. Lu and Z.H. Shi, Recent advance in the development of novel, selective and potent FGFR inhibitor, Eur. J. Med. Chem. 186 (2020), 111884;</ce:source-text>
                     <sb:reference id="bib13e">
                        <ce:label>e)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Yin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.L.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Natural products as important tyrosine kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>182</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>111664</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">B. Yin, D.M. Fang, X.L. Zhou and F. Gao, Natural products as important tyrosine kinase inhibitors, Eur. J. Med. Chem. 182 (2019) 111664;</ce:source-text>
                     <sb:reference id="bib13f">
                        <ce:label>f)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Golonko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lewandowska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Świsłocka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.T.</ce:given-name>
                                 <ce:surname>Jasińska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Priebe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Lewandowski</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin as tyrosine kinase inhibitor in cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>181</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>111512</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">A. Golonko, H. Lewandowska, R. Swislocka, U.T. Jasinska, W. Priebe and W. Lewandowski, Curcumin as tyrosine kinase inhibitor in cancer treatment, Eur. J. Med. Chem. 181 (2019) 111512.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Hartmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Haap</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.G.</ce:given-name>
                                 <ce:surname>Kopp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.P.</ce:given-name>
                                 <ce:surname>Lipp</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Drug Metabol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>470</sb:first-page>
                              <sb:last-page>481</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">J.T. Hartmann, M. Haap, H.G. Kopp, H.P. Lipp, Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects, Curr. Drug Metab. 10 (2009) 470-481.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Arora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Scholar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of tyrosine kinase inhibitors in cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pharmacol. Exp. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>315</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>971</sb:first-page>
                              <sb:last-page>979</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">A. Arora and E.M. Scholar, Role of tyrosine kinase inhibitors in cancer therapy, J. Pharmacol. Exp. Ther. 315 (2005) 971-979.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.M.</ce:given-name>
                                 <ce:surname>Eldehna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Fares</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Ibrahim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Aly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Ali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Abou-Seri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Abdel-Aziz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.A.</ce:given-name>
                                 <ce:surname>El Ella</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: synthesis, in vitro biological evaluation and molecular docking</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>100</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>89</sb:first-page>
                              <sb:last-page>97</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">W.M. Eldehna, M. Fares, H.S. Ibrahim, M.H. Aly, S. Zada, M.M. Ali, S.M. Abou-Seri, H.A. Abdel-Aziz, D.A.A. El Ella, Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking, Eur. J. Med. Chem. 100 (2015) 89-97.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.M.</ce:given-name>
                                 <ce:surname>Eldehna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>El Kerdawy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.H.</ce:given-name>
                                 <ce:surname>Al-Ansary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Al-Rashood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Ali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.E.</ce:given-name>
                                 <ce:surname>Mahmoud</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Type IIA-Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: design, synthesis, antiproliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>163</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>37</sb:first-page>
                              <sb:last-page>53</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">W.M. Eldehna, A.M. El Kerdawy, G.H. Al-Ansary, S.T. Al-Rashood, M.M. Ali, A.E. Mahmoud, Type IIA-Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, antiproliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides, Eur. J. Med. Chem. 163 (2019) 37-53.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="bib18a">
                        <ce:label>a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Safaie Qamsari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Safaei Ghaderi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zarei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Dorostkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bagheri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Jadidi-Niaragh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Somi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yousefi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The c-Met receptor: implication for targeted therapies in colorectal cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tumor Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>39</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>13</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">E. Safaie Qamsari, S. Safaei Ghaderi, B. Zarei, R. Dorostkar, S. Bagheri, F. Jadidi-Niaragh, M.H. Somi and M. Yousefi, The c-Met receptor: implication for targeted therapies in colorectal cancer, Tumor Biol.. 39 (2017) 1-13;</ce:source-text>
                     <sb:reference id="bib18b">
                        <ce:label>b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ouyang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>108</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>495</sb:first-page>
                              <sb:last-page>504</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">J. Zhang, X. Jiang, Y. Jiang, M. Guo, S. Zhang, J. Li, J. He, J. Liu, J. Wang, L. Ouyang, Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs, Eur. J. Med. Chem. 108 (2016) 495-504.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Aytaç</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Durmaz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Houston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Çetin-Atalay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Tozkoparan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>858</sb:first-page>
                              <sb:last-page>872</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">P.S. Aytac, I. Durmaz, D.R. Houston, R. Cetin-Atalay, B. Tozkoparan, Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins, Bioorg. Med. Chem. 24 (2016) 858-872.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mohamady</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Galal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.M.</ce:given-name>
                                 <ce:surname>Eldehna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Gutierrez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Ibrahim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Elmazar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.I.</ce:given-name>
                                 <ce:surname>Ali</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual targeting of VEGFR2 and C-Met kinases via the design and synthesis of substituted 3-(triazolo-thiadiazin-3-yl) indolin-2-one derivatives as angiogenesis inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Omega</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>18872</sb:first-page>
                              <sb:last-page>18886</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">S. Mohamady, M. Galal, W.M. Eldehna, D.C. Gutierrez, H.S. Ibrahim, M.M. Elmazar and H.I. Ali, Dual targeting of VEGFR2 and C-Met kinases via the design and synthesis of substituted 3-(triazolo-thiadiazin-3-yl) indolin-2-one derivatives as angiogenesis inhibitors, ACS omega 5 (2020) 18872-18886.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Jun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.J.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Hua</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Lei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Bing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Ying</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.F.</ce:given-name>
                                 <ce:surname>Qiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.B.</ce:given-name>
                                 <ce:surname>Bei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Guang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.X.</ce:given-name>
                                 <ce:surname>Tai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>53</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8140</sb:first-page>
                              <sb:last-page>8149</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">T.P. Cho, S.Y. Dong, F. Jun, F.J. Hong, Y.J. Liang, X. Lu, P.J. Hua, L.Y. Li, Z. Lei, H. Bing, Z. Ying, L.F. Qiong, F.B. Bei, L.L. Guang, G.A. Shen, S.G. Hong, S.W. Hong, M.X. Tai, Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives, J. Med. Chem. 53 (2010) 8140-8149.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.H.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.I.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and evaluation of novel 2-pyrrolidone-fused (2-oxoindolin-3-ylidene) methylpyrrole derivatives as potential multi-target tyrosine kinase receptor inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Molecules</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>913</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">T.H. Yang, C.I. Lee, W.H. Huang, A.R. Lee, Synthesis and evaluation of novel 2-pyrrolidone-fused (2-oxoindolin-3-ylidene) methylpyrrole derivatives as potential multi-target tyrosine kinase receptor inhibitors, Molecules 22 (2017) 913.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, Synthesis and preliminary biological evaluation of novel benzyl sulfoxide 2-indolinone derivatives as anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Molecules</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1979</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">L. Tang, T. Peng, G. Wang, X. Wen, Y. Sun, S. Zhang, S. Liu, L. Wang, Design, Synthesis and preliminary biological evaluation of novel benzyl sulfoxide 2-indolinone derivatives as anticancer agents, Molecules 22 (2017) 1979.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Weng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6953</sb:first-page>
                              <sb:last-page>6960</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">G. Chen, Q. Weng, L. Fu, Z. Wang, P. Yu, Z. Liu, X. Li, H. Zhang, G. Liang, Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents, Bioorg. Med. Chem. 22 (2014) 6953-6960.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="bib25a">
                        <ce:label>a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.X.</ce:given-name>
                                 <ce:surname>Cui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.B.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular diversity of trimethoxyphenyl-1, 2, 3-triazole hybrids as novel colchicine site tubulin polymerization inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>165</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>309</sb:first-page>
                              <sb:last-page>322</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">D.J. Fu, P. Li, B.W. Wu, X.X. Cui, C.B. Zhao and S.Y. Zhang, Molecular diversity of trimethoxyphenyl-1, 2, 3-triazole hybrids as novel colchicine site tubulin polymerization inhibitors, Eur. J. Med. Chem. 165 (2019) 309-322;</ce:source-text>
                     <sb:reference id="bib25b">
                        <ce:label>b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Naaz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>Pallavi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shafi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Mulakayala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Yar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>1, 2, 3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 and tubulin: their anti-proliferative and anti-inflammatory activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>81</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>20</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">F. Naaz, M.P. Pallavi, S. Shafi, N. Mulakayala, M.S. Yar and H.S. Kumar, 1, 2, 3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 and tubulin: their anti-proliferative and anti-inflammatory activity, Bioorg. Chem. 81 (2018) 1-20;</ce:source-text>
                     <sb:reference id="bib25c">
                        <ce:label>c)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Tu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Gong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel pyrrolo [2, 3-<ce:italic>b</ce:italic>] pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1680</sb:first-page>
                              <sb:last-page>1684</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">Q. Tang, L. Wang, Y. Tu, W. Zhu, R. Luo, Q. Tu, P. Wang, C. Wu, P. Gong and P. Zheng, Discovery of novel pyrrolo [2, 3-b] pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors, Bioorg. Med. Chem. Lett 26 (2016) 1680-1684;</ce:source-text>
                     <sb:reference id="bib25d">
                        <ce:label>d)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shankaraiah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Jadala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nekkanti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Senwar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Nagesh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shrivastava</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.G.M.</ce:given-name>
                                 <ce:surname>Naidu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sathish</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kamal</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of C3-tethered 1,2,3-triazolo-β-carboline derivatives: anticancer activity, DNA-binding ability, viscosity and molecular modeling studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>64</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>42</sb:first-page>
                              <sb:last-page>50</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">N. Shankaraiah, C. Jadala, S. Nekkanti, K.R. Senwar, N. Nagesh, S. Shrivastava, V.G.M. Naidu, M. Sathish and A. Kamal, Design and synthesis of C3-tethered 1,2,3-triazolo-β-carboline derivatives: anticancer activity, DNA-binding ability, viscosity and molecular modeling studies, Bioorg. Chem. 64 (2016) 42-50;</ce:source-text>
                     <sb:reference id="bib25e">
                        <ce:label>e)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.R.</ce:given-name>
                                 <ce:surname>Senwar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Jeengar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.L.</ce:given-name>
                                 <ce:surname>Nayak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.G.M.</ce:given-name>
                                 <ce:surname>Naidu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kamal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shankaraiah</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Spirooxindole-derived morpholine-fused-1,2,3-triazoles: design, synthesis, cytotoxicity and apoptosis inducing studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>413</sb:first-page>
                              <sb:last-page>424</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">K.R. Senwar, P. Sharma, T.S. Reddy, M.K. Jeengar, V.L. Nayak, V.G.M. Naidu, A. Kamal and N. Shankaraiah, Spirooxindole-derived morpholine-fused-1,2,3-triazoles: design, synthesis, cytotoxicity and apoptosis inducing studies, Eur. J. Med. Chem. 102 (2015) 413-424;</ce:source-text>
                     <sb:reference id="bib25f">
                        <ce:label>f)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ashwini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Garg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>Mohan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Fuchs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rangappa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Anusha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.R.</ce:given-name>
                                 <ce:surname>Swaroop</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Rakesh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kanojia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Madan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bender</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.P.</ce:given-name>
                                 <ce:surname>Koeffler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>Basappa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Rangappa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis of 1, 2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6157</sb:first-page>
                              <sb:last-page>6165</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">N. Ashwini, M. Garg, C.D. Mohan, J.E. Fuchs, S. Rangappa, S. Anusha, T.R. Swaroop, K.S. Rakesh, D. Kanojia, V. Madan, A. Bender, H.P. Koeffler, Basappa and K.S. Rangappa, Synthesis of 1, 2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation, Bioorg. Med. Chem. 23 (2015) 6157-6165;</ce:source-text>
                     <sb:reference id="bib25g">
                        <ce:label>g)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kamal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Prabhakar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Ramaiah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.V.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mallareddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shankaraiah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.N.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.N.C.V.L.</ce:given-name>
                                 <ce:surname>Pushpavalli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pal-Bhadra</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and anticancer activity of chalcone-pyrrolobenzodiazepine conjugates linked <ce:italic>via</ce:italic> 1,2,3-triazole ring side-armed with alkane spacers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>46</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3820</sb:first-page>
                              <sb:last-page>3831</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">A. Kamal, S. Prabhakar, M.J. Ramaiah, P.V. Reddy, C.R. Reddy, A. Mallareddy, N. Shankaraiah, T.L.N. Reddy, S.N.C.V.L. Pushpavalli, M. Pal-Bhadra, Synthesis and anticancer activity of chalcone-pyrrolobenzodiazepine conjugates linked via 1,2,3-triazole ring side-armed with alkane spacers, Eur. J. Med. Chem. 46 (2011) 3820-3831;</ce:source-text>
                     <sb:reference id="bib25h">
                        <ce:label>h)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kamal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shankaraiah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Devaiah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Juvekar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kurian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zingde</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis of 1,2,3-triazole-linked pyrrolobenzodiazepine conjugates employing ‘click’chemistry: DNA-binding affinity and anticancer activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1468</sb:first-page>
                              <sb:last-page>1473</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">A. Kamal, N. Shankaraiah, V. Devaiah, K.L. Reddy, A. Juvekar, S. Sen, N. Kurian, S. Zingde, Synthesis of 1,2,3-triazole-linked pyrrolobenzodiazepine conjugates employing ‘click’chemistry: DNA-binding affinity and anticancer activity, Bioorg. Med. Chem. Lett, 18 (2008) 1468-1473;</ce:source-text>
                     <sb:reference id="bib25i">
                        <ce:label>i)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Odlo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hentzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>dit Chabert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ducki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.A.</ce:given-name>
                                 <ce:surname>Gani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Sylte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Skrede</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.A.</ce:given-name>
                                 <ce:surname>Flørenes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.V.</ce:given-name>
                                 <ce:surname>Hansen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>1, 5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4829</sb:first-page>
                              <sb:last-page>4838</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">K. Odlo, J. Hentzen, J.F. dit Chabert, S. Ducki, O.A. Gani, I. Sylte, M. Skrede, V.A. Floerenes, and T.V. Hansen, 1, 5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin, Bioorg. Med. Chem. 16 (2008) 4829-4838.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.Q.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Xue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.H.</ce:given-name>
                                 <ce:surname>Qian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Mohamed O</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.H.</ce:given-name>
                                 <ce:surname>Meng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1, 2, 3-triazole scaffold</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>211</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>113083</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">D.P. Wang, K.L. Liu, X.Y. Li, G.Q. Lu, W.H. Xue, X.H. Qian, K. Mohamed O and F.H. Meng, Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1, 2, 3-triazole scaffold, Eur. J. Med. Chem. 211 (2021) 113083.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Qin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Gong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1778</sb:first-page>
                              <sb:last-page>1786</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">M. Qin, S. Yan, L. Wang, H. Zhang, Y. Tian, Y. Zhao, P. Gong, Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors, Bioorg. Med. Chem. 25 (2017) 1778-1786.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Qin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Meng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>115486</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0270">M. Qin, Y. Tian, X. Han, Q. Cao, S. Zheng, C. Liu, X. Wu, L. Liu, Y. Meng, X. Wang, H. Zhang and Y. Hou, Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity, Bioorg. Med. Chem. 28 (2020) 115486.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.M.</ce:given-name>
                                 <ce:surname>Eldehna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>El-Naggar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Hamed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Ibrahim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Ghabbour</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Abdel-Aziz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>One-pot three-component synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative breast cancer MDA-MB-231 cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Enzym. Inhib. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>309</sb:first-page>
                              <sb:last-page>318</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">W.M. Eldehna, D.H. El-Naggar, A.R. Hamed, H.S. Ibrahim, H.A. Ghabbour and H.A. Abdel-Aziz, One-pot three-component synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative breast cancer MDA-MB-231 cells, J Enzyme Inhib. Med. Chem. 33 (2018) 309-318.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="bib30a">
                        <ce:label>a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Krystof</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Uldrijan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cyclin-dependent kinase inhibitors as anticancer drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Drug Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>291</sb:first-page>
                              <sb:last-page>302</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">V. Krystof, S. Uldrijan, Cyclin-dependent kinase inhibitors as anticancer drugs, Curr. Drug Targets 11 (2010) 291-302;</ce:source-text>
                     <sb:reference id="bib30b">
                        <ce:label>b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.O.</ce:given-name>
                                 <ce:surname>Morgan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Principles of CDK regulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>374</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>131</sb:first-page>
                              <sb:last-page>134</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">D.O. Morgan, Principles of CDK regulation, Nature 374 (1995) 131-134.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Weinberg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The retinoblastoma protein and cell cycle control</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>81</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>323</sb:first-page>
                              <sb:last-page>330</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">R.A. Weinberg, The retinoblastoma protein and cell cycle control, Cell 81 (1995) 323-330.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.T.</ce:given-name>
                                 <ce:surname>Chiou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Shia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.T.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and evaluation of 3-ylideneoxindole acetamides as potent anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>98</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>12</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0295">C.T. Chiou, W.C. Lee, J.H. Liao, J.J. Cheng, L.C. Lin, C.Y. Chen, J.S. Song, M.H. Wu, K.S. Shia, W.T. Li, Synthesis and evaluation of 3-ylideneoxindole acetamides as potent anticancer agents, Eur. J. Med. Chem. 98 (2015) 1-12.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Idowu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cyclin-dependent kinases as drug targets for cell growth and proliferation disorders. A role for systems biology approach in drug development. Part II – CDKs as drug targets in hypertrophic cell growth. Modelling of drugs targeting CDKs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biotechnol. Biotechnol. Equip.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2712</sb:first-page>
                              <sb:last-page>2715</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0300">M.A. Idowu, Cyclin-dependent kinases as drug targets for cell growth and proliferation disorders. A role for systems biology approach in drug development. Part II - CDKs as drug targets in hypertrophic cell growth. Modelling of drugs targeting CDKs, Biotechnol. Biotechnol. Equip. 26 (2012) 2712-2715.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Al-Warhi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>El Kerdawy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Aljaeed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.E.</ce:given-name>
                                 <ce:surname>Ismael</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Ayyad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.M.</ce:given-name>
                                 <ce:surname>Eldehna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Abdel-Aziz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.H.</ce:given-name>
                                 <ce:surname>Al-Ansary</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis, biological evaluation and in silico studies of certain oxindole–indole conjugates as anticancer CDK inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Molecules</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2031</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0305">T. Al-Warhi, A.M. El Kerdawy, N. Aljaeed, O.E. Ismael, R.R. Ayyad, W.M. Eldehna, H.A. Abdel-Aziz, G.H. Al-Ansary, Synthesis, biological evaluation and in silico studies of certain oxindole-indole conjugates as anticancer CDK inhibitors, Molecules 25 (2020) 2031.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="bib35a">
                        <ce:label>a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Yadav</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Sakla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Tokala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Nyalam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Khurana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Digwal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Talla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Godugu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shankaraiah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kamal</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of 5-morpholino-thiophene-indole/oxindole hybrids as cytotoxic agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ChemistrySelect</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4356</sb:first-page>
                              <sb:last-page>4363</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0310">U. Yadav, A.P. Sakla, R. Tokala, S.T. Nyalam, A. Khurana, C.S. Digwal, V. Talla, C. Godugu, N. Shankaraiah, A. Kamal, Design and synthesis of 5-morpholino-thiophene-indole/oxindole hybrids as cytotoxic agents, Chemistry 5 (2020) 4356-4363;</ce:source-text>
                     <sb:reference id="bib35b">
                        <ce:label>b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.K.</ce:given-name>
                                 <ce:surname>Gediya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.C.</ce:given-name>
                                 <ce:surname>Njar</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Promise and challenges in drug discovery and development of hybrid anticancer drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expet Opin. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1099</sb:first-page>
                              <sb:last-page>1111</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0315">L.K. Gediya, V.C. Njar, Promise and challenges in drug discovery and development of hybrid anticancer drugs, Expet Opin. Drug Discov.. 4 (2009) 1099-1111.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Al-Warhi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Abo-Ashour</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Almahli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.J.</ce:given-name>
                                 <ce:surname>Alotaibi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Al-Sanea</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.H.</ce:given-name>
                                 <ce:surname>Al-Ansary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Ahmed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Elaasser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.M.</ce:given-name>
                                 <ce:surname>Eldehna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Abdel-Aziz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel [(<ce:italic>N</ce:italic>-alkyl-3-indolylmethylene) hydrazono] oxindoles arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and Bcl-2: synthesis, biological evaluation and in silico studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Enzym. Inhib. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1300</sb:first-page>
                              <sb:last-page>1309</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0320">T. Al-Warhi, M.F. Abo-Ashour, H. Almahli, O.J. Alotaibi, M.M. Al-Sanea, G.H. Al-Ansary, H.Y. Ahmed, M.M. Elaasser, W.M. Eldehna and H.A. Abdel-Aziz, Novel [(N-alkyl-3-indolylmethylene) hydrazono] oxindoles arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and Bcl-2: synthesis, biological evaluation and in silico studies, J. Enzyme Inhib. Med. Chem 35 (2020) 1300-1309.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.M.</ce:given-name>
                                 <ce:surname>Eldehna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Al-Rashood</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Al-Warhi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.O.</ce:given-name>
                                 <ce:surname>Eskandrani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Alharbi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>El Kerdawy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Enzym. Inhib. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>270</sb:first-page>
                              <sb:last-page>285</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0325">W.M. Eldehna, S.T. Al-Rashood, T. Al-Warhi, R.O. Eskandrani, A. Alharbi, A.M. El Kerdawy, Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and in silico studies, J Enzyme Inhib. Med. Chem. 36 (2020) 270-285.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kamal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Mahesh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.L.</ce:given-name>
                                 <ce:surname>Nayak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Babu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.B.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Shaik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Kapure</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Alarifi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of pyrrolospirooxindole derivatives as novel cyclin dependent kinase 4 (CDK4) inhibitors by catalyst-free, green approach</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>108</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>476</sb:first-page>
                              <sb:last-page>485</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0330">A. Kamal, R. Mahesh, V.L. Nayak, K.S. Babu, G.B. Kumar, A.B. Shaik, J.S. Kapure, A. Alarifi, Discovery of pyrrolospirooxindole derivatives as novel cyclin dependent kinase 4 (CDK4) inhibitors by catalyst-free, green approach, Eur. J. Med. Chem. 108 (2016) 476-485.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="bib39a">
                        <ce:label>a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.-Y.</ce:given-name>
                                 <ce:surname>Won</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-J.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.-Y.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.-G.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PAK4 signaling in health and disease: defining the PAK4–CREB axis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Exp. Mol. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0335">S.-Y. Won, J.-J. Park, E.-Y. Shin, E.-G. Kim, PAK4 signaling in health and disease: defining the PAK4-CREB axis, Exp. Mol. Med. 51 (2019) 11;</ce:source-text>
                     <sb:reference id="bib39b">
                        <ce:label>b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nekrasova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Hao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Suh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Minden</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1215</sb:first-page>
                              <sb:last-page>1224</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0340">Y. Liu, H. Xiao, Y. Tian, T. Nekrasova, X. Hao, H.J. Lee, N. Suh, C.S. Yang, A. Minden, The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice, Mol. Canc. Res. 6 (2008) 1215-1224.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Piraino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Westwick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lamerdin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Dagostino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Knighton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Loi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zager</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Kraynov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Popoff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Christensen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Martinez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Kephart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Marakovits</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Karlicek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bergqvist</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Smeal</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>107</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9446</sb:first-page>
                              <sb:last-page>9451</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0345">B.W. Murray, C. Guo, J. Piraino, J.K. Westwick, C. Zhang, J. Lamerdin, E. Dagostino, D. Knighton, C.M. Loi, M. Zager, E. Kraynov, I. Popoff, J.G. Christensen, R. Martinez, S.E. Kephart, J. Marakovits, S. Karlicek, S. Bergqvist, T. Smeal, Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth, Proc. Natl. Acad. Sci. U.S.A 107 (2010) 9446-9451.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.F.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.D.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.R.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effects of PAK4/LIMK1/Cofilin-1 signaling pathway on proliferation, invasion, and migration of human osteosarcoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Lab. Anal.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>e23362</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0350">Z.F. Li, Y.D. Yao, Y.Y. Zhao, Y. Liu, Z.H. Liu, P. Hu and Z.R. Zhu, Effects of PAK4/LIMK1/Cofilin-1 signaling pathway on proliferation, invasion, and migration of human osteosarcoma cells, J. Clin. Lab. Anal. 34 (2020) e23362.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of indolin-2-one derivatives as potent PAK4 inhibitors: structure-activity relationship analysis, biological evaluation and molecular docking study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3500</sb:first-page>
                              <sb:last-page>3511</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0355">J. Guo, M. Zhu, T. Wu, C. Hao, K. Wang, Z. Yan, W. Huang, J. Wang, D. Zhao and M. Cheng, Discovery of indolin-2-one derivatives as potent PAK4 inhibitors: Structure-activity relationship analysis, biological evaluation and molecular docking study, Bioorg. Med. Chem. 25 (2017) 3500-3511.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Pang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, structure-activity relationships study and X-ray crystallography of 3-substituted-indolin-2-one-5-carboxamide derivatives as PAK4 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>155</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>197</sb:first-page>
                              <sb:last-page>209</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0360">J. Guo, F. Zhao, W. Yin, M. Zhu, C. Hao, Y. Pang, T. Wu, J. Wang, D. Zhao, H. Li, M. Cheng, Design, synthesis, structure-activity relationships study and X-ray crystallography of 3-substituted-indolin-2-one-5-carboxamide derivatives as PAK4 inhibitors, Eur. J. Med. Chem. 155 (2018) 197-209.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.Z.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Q.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Cancer Drug Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2</sb:first-page>
                              <sb:last-page>6</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0365">L.H. Wang, G.Z. Cheng, S. Park, S. Shu, L. He, W. Kong, W. Zhang, Z. Yuan, J.Q. Cheng, Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery, Curr. Cancer Drug Targets 8 (2008) 2-6.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Nagarsenkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Prajapti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>Guggilapu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Birineni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Kotapalli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ummanni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.N.</ce:given-name>
                                 <ce:surname>Babu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Investigation of triazole-linked indole and oxindole glycoconjugates as potential anticancer agents: novel Akt/PKB signaling pathway inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>MedChemComm</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>646</sb:first-page>
                              <sb:last-page>653</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0370">A. Nagarsenkar, S.K. Prajapti, S.D. Guggilapu, S. Birineni, S.S. Kotapalli, R. Ummanni, B.N. Babu, Investigation of triazole-linked indole and oxindole glycoconjugates as potential anticancer agents: novel Akt/PKB signaling pathway inhibitors, MedChemComm 7 (2016), 646-653.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Naz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Anjum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Islam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ahmad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.I.</ce:given-name>
                                 <ce:surname>Hassan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Microtubule affinity-regulating kinase 4: structure, function, and regulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Biochem. Biophys.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>67</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>485</sb:first-page>
                              <sb:last-page>499</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0375">F. Naz, F. Anjum, A. Islam, F. Ahmad, M.I. Hassan, Microtubule affinity-regulating kinase 4: structure, function, and regulation, Cell Biochem. Biophys. 67 (2013) 485-499.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Aneja</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Khan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Khan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Queen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hussain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Rehman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Alajmi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>El-Seedi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.I.</ce:given-name>
                                 <ce:surname>Hassan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Abid</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>163</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>840</sb:first-page>
                              <sb:last-page>852</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0380">B. Aneja, N.S. Khan, P. Khan, A. Queen, A. Hussain, M.T. Rehman, M.F. Alajmi, H.R. El-Seedi, S. Ali, M.I. Hassan, M. Abid, Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis, Eur. J. Med. Chem. 163 (2019) 840-852.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Maniswami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Prashanth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Karanth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Koushik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Govindaraj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Mullangi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rajagopal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Jegatheesan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PLK4: a link between centriole biogenesis and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Ther. Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>59</sb:first-page>
                              <sb:last-page>73</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0385">R.R. Maniswami, S. Prashanth, A.V. Karanth, S. Koushik, H. Govindaraj, R. Mullangi, S. Rajagopal, S.K. Jegatheesan, PLK4: a link between centriole biogenesis and cancer, Expert Opin. Ther. Targets 22 (2018) 59-73.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.A.</ce:given-name>
                                 <ce:surname>Barr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.H.</ce:given-name>
                                 <ce:surname>Silljé</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Nigg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Polo-like kinases and the orchestration of cell division</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>429</sb:first-page>
                              <sb:last-page>441</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0390">F.A. Barr, H.H. Sillje, E.A. Nigg, Polo-like kinases and the orchestration of cell division, Nat. Rev. Mol. Cell Biol. 5 (2004) 429-441.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Judge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Robbins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Tavakoli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Levi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Fronda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Ambegia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>McClintock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>MacLachlan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Invest.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>119</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>661</sb:first-page>
                              <sb:last-page>673</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0395">A.D. Judge, M. Robbins, I. Tavakoli, J. Levi, L. Hu, A. Fronda, E. Ambegia, K. McClintock and I. MacLachlan, Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice, J. Clin. Investig. 119 (2009) 661-673.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Laufer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Forrest</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sampson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Edwards</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Lang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Awrey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Plotnikova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hodgson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Beletskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Mason</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Feher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ban</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kiarash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Green</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Mak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.W.</ce:given-name>
                                 <ce:surname>Pauls</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The discovery of PLK4 inhibitors:(<ce:italic>E</ce:italic>)-3-((1 <ce:italic>H</ce:italic>-Indazol-6-yl) Methylene) indolin-2-ones as novel antiproliferative agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6069</sb:first-page>
                              <sb:last-page>6087</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0400">R. Laufer, B. Forrest, S.W. Li, Y. Liu, P. Sampson, L. Edwards, Y. Lang, D.E. Awrey, G. Mao, O. Plotnikova, G. Leung, R. Hodgson, I. Beletskaya, J.M. Mason, X. Luo, X. Wei, Y. Yao, M. Feher, F. Ban, R. Kiarash, E. Green, T.W. Mak, G. Pan, H.W. Pauls, The discovery of PLK4 inhibitors:(E)-3-((1 H-Indazol-6-yl) Methylene) indolin-2-ones as novel antiproliferative agents, J. Med. Chem. 56 (2013) 6069-6087.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Sampson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.K.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Feher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Forrest</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Edwards</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Laufer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Lang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ban</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Awrey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Plotnikova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hodgson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Mason</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kiarash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Green</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Qui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.Y.</ce:given-name>
                                 <ce:surname>Chirgadze</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Mak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.W.</ce:given-name>
                                 <ce:surname>Pauls</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The discovery of polo-like kinase 4 inhibitors: design and optimization of spiro [cyclopropane-1, 3′[3<ce:italic>H</ce:italic>] indol]-2′(1′<ce:italic>H</ce:italic>)-ones as orally bioavailable antitumor agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>130</sb:first-page>
                              <sb:last-page>146</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0405">P.B. Sampson, Y. Liu, N.K. Patel, M. Feher, B. Forrest, S.W. Li, L. Edwards, R. Laufer, Y. Lang, F. Ban, D.E. Awrey, G. Mao, O. Plotnikova, G. Leung, R. Hodgson, J. Mason, X. Wei, R. Kiarash, E. Green, W. Qui, N.Y. Chirgadze, T.W. Mak, G. Pan, H.W. Pauls, The discovery of polo-like kinase 4 inhibitors: Design and optimization of spiro [cyclopropane-1, 3′[3H] indol]-2′(1′H)-ones as orally bioavailable antitumor agents, J. Med. Chem. 58 (2015) 130-146.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Sampson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Forrest</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cumming</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.K.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Edwards</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Laufer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Feher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ban</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Awrey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Plotnikova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hodgson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Beletskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Mason</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Nadeem</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kiarash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Madeira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Mak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.W.</ce:given-name>
                                 <ce:surname>Pauls</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The discovery of polo-like kinase 4 inhibitors: identification of (1<ce:italic>R</ce:italic>, 2<ce:italic>S</ce:italic>)-2-(3-((<ce:italic>E</ce:italic>)-4-(((<ce:italic>cis</ce:italic>)-2, 6-dimethylmorpholino) methyl) styryl)-1<ce:italic>H</ce:italic>-indazol-6-yl)-5′-methoxyspiro [cyclopropane-1, 3′-indolin]-2′-one (CFI-400945) as a potent, orally active antitumor agent</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>147</sb:first-page>
                              <sb:last-page>169</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0410">P.B. Sampson, Y. Liu, B. Forrest, G. Cumming, S.W. Li, N.K. Patel, L. Edwards, R. Laufer, M. Feher, F. Ban, D.E. Awrey, G. Mao, O. Plotnikova, R. Hodgson, I. Beletskaya, J.M. Mason, X. Luo, V. Nadeem, X. Wei, R. Kiarash, B. Madeira, P. Huang, T.W. Mak, G. Pan, H.W. Pauls, The discovery of polo-like kinase 4 inhibitors: Identification of (1R, 2S)-2-(3-((E)-4-(((cis)-2, 6-dimethylmorpholino) methyl) styryl)-1H-indazol-6-yl)-5′-methoxyspiro [cyclopropane-1, 3′-indolin]-2′-one (CFI-400945) as a potent, orally active antitumor agent, J. Med. Chem. 58 (2015) 147-169.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Pang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.G.</ce:given-name>
                                 <ce:surname>Yeoh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Thorn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.B.</ce:given-name>
                                 <ce:surname>Lilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Salto-Tellez</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potential roles for the PIM1 kinase in human cancer–a molecular and therapeutic appraisal</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>44</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2144</sb:first-page>
                              <sb:last-page>2151</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0415">N. Shah, B. Pang, K.G. Yeoh, S. Thorn, C.S. Chen, M.B. Lilly, M. Salto-Tellez, Potential roles for the PIM1 kinase in human cancer-a molecular and therapeutic appraisal, Eur. J. Cancer 44 (2008) 2144-2151.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Merkel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Meggers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ocker</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PIM1 kinase as a target for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expet Opin. Invest. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>425</sb:first-page>
                              <sb:last-page>436</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0420">A.L. Merkel, E. Meggers, M. Ocker, PIM1 kinase as a target for cancer therapy, Expert Opin. Investig. Drugs 21 (2012) 425-436.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.B.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.B.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.D.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.F.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and biological evaluation of novel C3-functionalized oxindoles as potential PIM1 kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>RSC Adv.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>29456</sb:first-page>
                              <sb:last-page>29466</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0425">H.B. Sun, X.Y. Wang, G.B. Li, L.D. Zhang, J. Liu, L.F. Zhao, Design, synthesis and biological evaluation of novel C3-functionalized oxindoles as potential PIM1 kinase inhibitors, RSC Adv. 5 (2015) 29456-29466.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.I.</ce:given-name>
                                 <ce:surname>Feldman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Polokoff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Kochanny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Dinter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Biroc</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Alicke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bryant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.O.</ce:given-name>
                                 <ce:surname>Buckman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Lentz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ferrer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Whitlow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Alder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Finster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.O.</ce:given-name>
                                 <ce:surname>Arnaiz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>280</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>19867</sb:first-page>
                              <sb:last-page>19874</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0430">R.I. Feldman, J.M. Wu, M.A. Polokoff, M.J. Kochanny, H. Dinter, D. Zhu, S.L. Biroc, B. Alicke, J. Bryant, S. Yuan, B.O. Buckman, D. Lentz, M. Ferrer, M. Whitlow, M. Alder, S. Finster, Z. Chang, D.O. Arnaiz, Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1, J. Biol. Chem. 280 (2005) 19867-19874.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Vivanco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Sawyers</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The phosphatidylinositol 3-kinase–AKT pathway in human cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>489</sb:first-page>
                              <sb:last-page>501</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0435">I. Vivanco and C.L. Sawyers, The phosphatidylinositol 3-kinase-AKT pathway in human cancer, Nat. Rev. Cancer 2 (2002) 489-501.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sestito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Nesi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Daniele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Martelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Digiacomo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Borghini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pietra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Calderone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lapucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Falasca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Parrella</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>105</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>274</sb:first-page>
                              <sb:last-page>288</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0440">S. Sestito, G. Nesi, S. Daniele, A. Martelli, M. Digiacomo, A. Borghini, D. Pietra, V. Calderone, A. Lapucci, M. Falasca, P. Parrella, Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme, Eur. J. Med. Chem. 105 (2015) 274-288.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bavetsias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Linardopoulos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora kinase inhibitors: current status and outlook</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>278</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0445">V. Bavetsias and S. Linardopoulos, Aurora kinase inhibitors: current status and outlook, Front. Oncol. 5 (2015) 278.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.Y.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Lubet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Bode</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of an Aurora kinase inhibitor specific for the Aurora B isoform</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>73</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>716</sb:first-page>
                              <sb:last-page>724</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0450">H. Xie, M.H. Lee, F. Zhu, K. Reddy, C. Peng, Y. Li, D.Y. Lim, D.J. Kim, X. Li, S. Kang, H. Li, W. Ma, R.A. Lubet, J. Ding, A.M. Bode and Z. Dong, Identification of an Aurora kinase inhibitor specific for the Aurora B isoform, Cancer Res. 73 (2013) 716-724.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Daniele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sestito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pietrobono</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Giacomelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chiellini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Di Maio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Marinelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Novellino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Martini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rapposelli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual inhibition of PDK1 and Aurora Kinase A: an effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Neurosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>100</sb:first-page>
                              <sb:last-page>114</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0455">S. Daniele, S. Sestito, D. Pietrobono, C. Giacomelli, G. Chiellini, D. Di Maio, L. Marinelli, E. Novellino, C. Martini and S. Rapposelli, Dual inhibition of PDK1 and Aurora Kinase A: an effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells, ACS Chem. Neurosci. 8 (2017) 100-114.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dandapani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Hardie</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Soc. Trans.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>687</sb:first-page>
                              <sb:last-page>693</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0460">M. Dandapani and D.G. Hardie, AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells?, Biochem. Soc. Trans. 41 (2013) 687-693.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Matheson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Casalvieri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Backos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Minhajuddin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.T.</ce:given-name>
                                 <ce:surname>Jordan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Reigan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>197</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>112316</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0465">C.J. Matheson, K.A. Casalvieri, D.S. Backos, M. Minhajuddin, C.T. Jordan, P. Reigan, Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors, Eur. J. Med. Chem. 197 (2020) 112316.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bort</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Quesada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Á.</ce:given-name>
                                 <ce:surname>Ramos-Torres</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gargantilla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Priego</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Raynal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Lepifre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Gasalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Rodriguez-Henche</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Castro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Díaz-Laviada</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of a novel 2-oxindole fluorinated derivative as in vivo antitumor agent for prostate cancer acting via AMPK activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>No. 4370</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0470">A. Bort, S. Quesada, A. Ramos-Torres, M. Gargantilla, E.M. Priego, S. Raynal, F. Lepifre, J.M. Gasalla, N. Rodriguez-Henche, A. Castro, I. Diaz-Laviada, Identification of a novel 2-oxindole fluorinated derivative as in vivo antitumor agent for prostate cancer acting via AMPK activation, Sci. Rep. 8 (2018) No. 4370.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>